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Cancer immunotherapy and especially immune checkpoint blockade therapy has 
revolutionized cancer treatment in many tumor types including breast cancer (BC). The 
expression and specific role of Programmed Death-1 (PD-1)/Programmed Death-Ligand 1 
(PD-L1) signaling axis, immune-related gene signatures and immune cell subpopulations needs 
to be fully elucidated while the identification of prognostic and predictive biomarkers in BC is 
of utmost importance. 
The overall aim of the thesis was to investigate the expression, prognostic/predictive 
implications and regulatory mechanisms of the PD-1/PD-L1 checkpoints and immune infiltrate 
in early and advanced BC. 
In paper I, a comprehensive analysis of PD-L1 expression patterns and its prognostic 
implications was performed in early BC. PD-L1 protein expression was mostly expressed in 
immune cells and was most abundant in the TNBC subtype. PD-L1 expression in tumor cells 
was a poor prognostic factor whereas PD-L1 expression in immune cells was correlated with 
improved survival outcomes in TNBC, as revealed in a trial-level meta-analysis including 38 
studies. PD-L1 gene expression was associated with improved prognosis in the entire 
population as revealed in a pooled transcriptomic analysis of 39 publicly available datasets. 
PD-L1 expression can therefore represent a promising clinically relevant biomarker of good 
prognosis which can also select appropriate candidates for immunotherapy. 
 
In paper II, PD-L1 expression was evaluated both at the protein and mRNA level in the same 
retrospective early BC patient cohort. Both protein (stained with the antibody clone SP263) 
and gene expression predicted improved outcome in early BC and also correlated with 
enhanced T-cell infiltration (CD3+ IHC and in silico estimation of CD8+/CD4+ T-cells). Of 
note, PD-L1 mRNA expression can add significant prognostic value to the prospectively 
validated 21- and 70-gene gene signatures in ER+/HER2- disease. Upon validation, this finding 
might improve prognostication capacity of the current gene signatures.   
 
In paper III, we investigated the role of STAT3 as a regulator of PD-L1 expression and immune 
response in BC in vitro, in vivo and in BC patient samples. A positive correlation between 
STAT3 and PD-L1 was observed at the protein and gene expression level while a 
transcriptional STAT3-mediated regulation of PD-L1 was demonstrated in BC cells. Of note, 
STAT3 modulated antitumor immune response mainly through macrophage phenotype shift 
and accumulation of NK cells rather than via cytotoxic T-cell infiltration in a murine BC model. 
Furthermore, pro-tumoral macrophages were correlated with PD-L1 expression in BC patient 
tumors, thus providing insights on the tumor-immune cell interactions and potential clinical 
implications. 
 
In paper IV, a multi-level study of the prognostic capacity of PD-1 expression in early BC was 
performed including: a) a study cohort with IHC and GEP data, b) systematic review and trial-
level IHC-based meta-analysis of 15 studies and c) pooled analysis of publicly available 
transcriptomic datasets). PD-1 protein and gene expression were correlated with improved OS 
in the entire population of the study cohort. In the pooled analyses PD-1 protein and gene 
expressions were correlated with better survival outcomes in TNBC/basal-like patients and 
therefore is a promising biomarker which merits further validation. 
 
In paper V the role of relevant gene signatures as predictors of response to chemotherapy was 
investigated in patients (n=109) with advanced BC participating in the translational sub-study 
of the phase III TEX trial. Fine-needle aspiration biopsies were used for gene expression 
profiling and for TILs enumeration. Immune-related gene signatures predicted better response 
to chemotherapy in ER+ and luminal BC patients which was further confirmed through an 
independent gene set enrichment and other in silico analyses. The lymphocytic abundance was 
low and predicted no effect to chemotherapy. These results may pave the way for the 
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1 INTRODUCTION 
 
Breast cancer (BC) is the most common malignancy and the leading cause of cancer death in 
women worldwide (1). Owing to advances in treatment and early detection by screening (2), 
death rates in BC have decreased and 5-year survival presently exceeds 75% in most western 
countries (3, 4). In the metastatic setting, however the disease is not curable and treatment has 
a palliative intention. Despite an extended arsenal of different cytotoxic, endocrine and targeted 
therapies the long-term prognosis is poor with a median survival of less than two years in the 
population level (5). 
Breast cancer is a heterogeneous disease both clinically and biologically. According to the 
immunohistochemical expression of hormone receptors (ΗR) (estrogen receptor, ER; 
progesterone receptor, PR) and human epidermal growth factor receptor 2 (HER2), there are 
three major different BC subtypes:  
i. ER-positive, HER2-negative (ER+/HER2-), which represents the most common 
subtype (approx. 70%). Although it is correlated with the best prognosis, a steady rate 
of recurrence has been described even 20 years after endocrine threrapy (6). 
ii. HER2-positive (HER2+) (approx. 20% of the cases); it was initially associated with 
adverse clinical outcome (7) but the development of anti-HER2 targeted agents has 
revolutionized the management of these patients, thus prolonging survival rates. 
iii. Triple-Negative BC (TNBC) where none of the aforementioned markers are expressed 
(approx. 10-20%) . This subtype is the most aggressive one, associatted with the worst 
survival outcomes (8). 
Moreover, apart from the clinical subtypes which can indicate the underlying molecular BC 
heterogeneity, genomic studies have also revealed four distinct biological “intrinsic” subtypes. 
These include i) luminal A, ii) luminal B, iii) HER2-enriched and iv) basal-like (9).  
 
1.1 Adjuvant and neoadjuvant treatment in breast cancer 
The use of adjuvant polychemotherapy is associated with benefits in relapse-free survival 
(RFS) and overall survival (OS) in patients with early BC, regardless of clinicopathological 
factors (10). Recently the concept of dose-dense adjuvant chemotherapy administration has 
resulted into moderately reduced 10-year risk of recurrence and death from BC as compared to 
standard-schedule chemotherapy administration (11). Furthermore, in patients with 
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HR+/HER2- and HER2+ non-metastatic BC, endocrine therapy and HER2-targeted treatment 
should be offered, respectively (12).  
On the other hand, the use neoadjuvant treatment (NAT) leads to increased rates of breast-
conserving surgery and favorable long-term survival outcomes in patients achieving pathologic 
complete response (pCR) (13). The efficacy of neoadjuvant chemotherapy is shown to be 
equivalent to adjuvant chemotherapy (14), thus enabling the development of clinical trials and 
translational research platforms (i.e. investigation of tumor biology and heterogeneity). 
However, there are still patients who will experience disease relapse and others who will be 
exposed to unnecessary toxicities due to overtreatment. Therefore, there is a need for 
identification of reliable biomarkers which can stratify patients at risk and also guide treatment 
decisions. 
 
1.2 Prognostic and predictive biomarkers in breast cancer  
A biomarker/factor is prognostic when it can inform about the clinical outcome irrespective of 
any provided treatment. On the other hand, a predictive biomarker informs about the potential 
benefit that patients could gain from a specific therapeutic intervention (15). In order a 
biomarker to be implemented in clinical routine, it should prove its analytical validity (which 
reflects the technical issues of a test including accuracy and reproducibility), clinical validity 
(which reflects the capacity of a factor to distinguish subgroups with different 
biological/clinical outcomes) and clinical utility (which reflects usefulness of a factor for direct 
patient care and its ability to impact outcome when used), principles ensuring that a factor can 
be precise, reproducible, easily interpretable (16, 17). In BC, known prognostic factors include: 
age, race, pathologic factors (such as tumor stage, tumor size, lymph node involvement, 
presence of metastatic disease, tumor morphology, histologic grade, perivascular 
lymphovascular invasion) as well as tissue markers (i.e. ER and HER2 status represent 
prognostic factors and in addition they can predict benefit of treatment with hormonal and anti-
HER2 therapy, respectively) and proliferation markers (e.g Ki-67) (18, 19).  Furthermore, the 
optimization and validation of specific gene expression profiling (GEP) patterns has led to the 




  3 
1.3 Gene expression signatures as prognostic & predictive factors in early breast 
cancer 
The rapid advances in technology have enabled the introduction and wide use of gene 
expression profiling as a useful tool in clinical medicine (20, 21). Especially in BC, gene 
expression signatures have been developed in order to predict the risk of recurrence but also 
importantly to distinguish patients who will benefit from chemotherapy de-escalation 
strategies.  Several gene signatures have been developed namely: 21-gene (Recurrence score-
RS, commercially Oncotype DX), 70-gene signature (commercially, Mammaprint), 
EndoPredict, Prediction Analysis of Microaaray 50 (PAM50) (Risk-of-Recurrence, ROR; 
commercially, Prosigna) and Genomic Grade Index (GGI) and their prognostic capacity has 
been compared in previous studies (22). Only two of these gene signatures, the 21-gene and 
70-gene signature, have demonstrated their clinical utility through validation in the prospective 
randomized clinical trials TAILORx (23) and MINDACT (24), respectively. High RS is 
associated with high risk of recurrence and also predicts benefit from adjuvant chemotherapy 
in ER-positive/HER2- BC patients (25). By contrast, ER+, node-negative BC patients with low 
and intermediate RS (for the latter should be also >50 years old) can safely forego 
chemotherapy (26). In the MINDACT trial, patients with high clinical risk and low genomic 
risk according to the 70-gene signature had an excellent 5-year distant metastasis-free survival 
(DMFS) rate (94.7%, 95% CI 92.5 – 96.2) without receiving chemotherapy, although a trend 
in favor of chemotherapy was noted in this group (24). However, the use of these and the other 
gene signatures needs to be further refined and some questions remain to be addressed, since 
their benefit has been shown mostly node-negative patients while the data are limited for the 
node-positive disease (27).  
 
1.4 Tumor immunology and immunoediting   
Cancer development and progression has long been known to raise a anti-tumor immune 
response through which cancer cells can be eradicated by the immune system, unless they 
manage to escape immune recognition or create an immunosuppressive environment (28). The 
concept of immune surveillance describes the complex interactions between immune-host and 
tumor cells (Figure 1) and comprised three stages: elimination, equilibrium and evasion. 
Therefore, the ability of tumors to escape from immune destruction has been characterized as 
a hallmark of cancer (28, 29).  
The generation of the complex cyclic process of cancer-immunity interaction leading to the 
effective anti-tumor immune surveillance (30, 31)  includes the following steps: 1. release of 
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cancer cell antigens (neoantigens) as derived by immunogenic/tolerogenic cancer cell death 
and processing by antigen-presenting cells (3), 2. presentation of neoantigens to T-cells by 
APCs on the major histocompatibility complex I (MHC I) and II (MHC II), 3. priming and 
activation of T-cells against cancer antigens, 4. trafficking and 5. infiltration of 
effector/cytotoxic T-cells to tumor bed, 6. recognition of cancer cells (via T-cell receptors, 
MHC and other co-stimulatory molecules) and 7. killing of cancer cells.  
The anti-tumor immune response in BC can be different according to the disease subtype. 
TNBC subtype is considered to be highly heterogeneous and more immunogenic as compared 
to luminal subtype (32, 33). This trait can also be attributed to its higher mutational load despite 
that conflicting data have been reported regarding the association between mutational load and 
host immune response. On the one hand, higher genomic heterogeneity can generate 
neoantigens and therefore a stronger anti-tumor immune response whereas a decreased immune 
infiltrate can impair anti-tumor immune surveillance and can trigger intra-tumoral clonal 




Figure 1. Complex tumor-immune cell interactions in the tumor microenvironment (TME) 
(Chrétien et al., Cancers 2019) 
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1.5 Tumor infiltrating lymphocytes (TILs) and host immune response as prognostic 
and predictive biomarkers in early and metastatic breast cancer  
1.5.1 Prognostic value  
Breast cancer has been traditionally considered as a non-immunogenic or “immune-cold” 
tumor mainly due to its lower mutational load compared to other tumor types such as melanoma 
or non-small cell lung carcinoma (35, 36). However, infiltration of breast tumors by TILs is 
common especially among the TNBC and HER2+ subtypes (37, 38), which is generally 
reflecting an immunologic response against the tumor. 
The presence of lymphocytic infiltrate has been extensively explored as a prognostic 
biomarker. In early stage TNBC subtype, stromal TILs (sTILs) after adjuvant chemotherapy 
were independent prognostic factors of improved disease-free survival (DFS) and OS, as 
revealed in a recent pooled individual patient data analysis (n= 2148) from nine clinical trials 
(39).  Similar associations have been previously reported in prospective-retrospective analyses 
of clinical trials in TNBC (i.e. BIG 02-98, FinHER, ECOG 2197 and ECOG 1199) (40-42), 
further supporting the higher immunogenicity/lymphocytic infiltration and its favorable impact 
on improved survival outcomes. In another large pooled analysis including a total of 3771 
patients from six randomized trials from the German Breast Cancer Group, both TNBC and 
HER2+ subtypes, high levels of TILs have been correlated to improved DFS (43). In contrast, 
existing data for TILs in ER+ BC (the lowest levels among subtypes) do not support their use 
as prognostic biomarkers in these tumors (37, 44). 
Of note, in a recent paper including a pooled analysis of four cohorts of early TNBC patients 
(n=476) who were not treated with adjuvant chemotherapy, higher stromal TILs levels were 
independently correlated with increased DFS and OS. Excellent prognosis has also been 
demonstrated in patients with pathological stage I and high sTILs, and might represent a target 
group for chemotherapy de-escalation strategies (45). 
The aforementioned observations have led to the characterization of the lymphocyte-
predominant breast cancer (LPBC) subtype, defined as ³50% of the tumor area occupied by 
TILs as evaluated in H&E stained tumor sections (46) (see also below TILs evaluation 
methodology and future perspectives) which will also be also incorporated in the updated Word 




1.5.2 Predictive value  
1.5.2.1 Response to chemotherapy (neoadjuvant and adjuvant)  
Several studies have highlighted the role of TILs as biomarkers for predicting benefit from both 
adjuvant and neoadjuvant chemotherapy (43, 48).  
The phase III randomized GeparSixto trial including TNBC and HER2+ patients who received 
NAT the combination of anthracyclines-taxanes and trastuzumab +/- carboplatin reported that 
LPBC patients presented with higher pCR rates when receiving carboplatin, further suggesting 
that TILs can predict benefit and sensitivity to a specific chemotherapy regimen (48). However, 
the presence of high lymphocytic infiltration as described in a later study by Denkert et al. can 
predict response to NAT and leads to increased pCR rates in all subtypes (43).  
In the adjuvant setting, the effect of stromal TILs was favorable regardless of the chemotherapy 
regimen used (anthracycline-based chemotherapy with or without taxanes) in a large TNBC 
pooled analysis (39). Interestingly, in the secondary analysis BIG 02-98 trial, HER2+ breast 
patients with high stromal TILs values were significantly associated with benefit from 
anthracycline-only regimen as compared to anthracycline-docetaxel combination; significant 
interaction for both DFS and OS was noted (40). 
 
1.5.2.2 Response to anti-HER2 therapies (adjuvant and neoadjuvant)  
In the HER2+ subtype, controversial data have been reporting on the predictive role of TILs to 
adjuvant trastuzumab treatment. In the FinHER study, TILs were significantly associated with 
survival benefit from trastuzumab (41). In contrast, the N9831 study (n=945) demonstrated an 
association of high sTILs with improved relapse-free survival only in the chemotherapy arm 
and not in the trastuzumab (49) while similar results of a non-significant interaction between 
high sTILs and trastuzumab benefit were demonstrated in the NSABP B-31 study (50).  
Regarding treatment duration and immune response, it has been reported in the ShortHER trial 
that patients with low TILs had a greater treatment benefit from 1-year as compared to 9-weeks 
trastuzumab (+chemotherapy). On the other hand, patients with high TILs had an improved 
DFS regardless of trastuzumab duration (51). 
In the neoadjuvant setting, TILs have been investigated as pCR predictors in prospective-
retrospective analyses of many trials using anti-HER2 therapies. Of note, it was in a meta-
analysis including 1,256 patients treated with chemotherapy and trastuzumab, lapatinib (or 
combination) in five randomized phase 3 trials (CherLOB, NeoALLTO, GeparQuattro, 
GeparQuinto and GeparSixto), that baseline sTILs levels were associated with higher pCR rates 
irrespective of the anti-HER2 or chemotherapy agents used (48, 52-55). 
 
  7 
1.6 Temporal expression of TILs and prognostic implications in breast cancer  
1.6.1 Tumor-infiltrating lymphocytes in the metastatic versus primary breast 
tumors  
The role of TILs in BC metastatic setting has not been fully elucidated since data are scarce. 
Although consensus recommendations for the evaluation of TILs include metastatic tissues 
(56), their evaluation has not always proven to be successful (see also paper V) (57) and 
remains challenging. In the CLEOPATRA randomized phase 3 trial, including 678 HER2+ 
metastatic BC patients with evaluable tumor samples, higher levels of stromal TILs were 
significantly associated with prolonged OS, regardless of treatment group (docetaxel and 
trastuzumab combined with either pertuzumab or placebo) (58). In contrast, in another 
randomized phase 3 study (The Canadian Cancer Trials Group MA.31 trial) of metastatic 
HER2-positive patients receiving trastuzumab or lapatinib in combination with taxane, no 
significant prognostic or predictive effect was observed in the high-TILs group (59).  
Moreover, a few previous reports have demonstrated that the number of TILs was lower in 
metastases compared to the primary tumor, especially in the TNBC and HER2+ subtypes (60-
63). Metastatic BC patients with higher TILs had improved survival as compared to those with 
lower TILs expression levels (62). Among specific immune cell subpopulations, CD4+ and 
CD8+ T-cells also significantly decreased in the metastatic lesions (60, 61), while some studies 
have also investigated the differential expression of T-regulatory cells (T-regs) (60, 62). Of 
note, macrophage expression markers evaluated by gene expression profiling remained highly 
expressed in the metastatic sites (63), while CD68+ IHC expression in BC brain metastases 
was independently associated with improved survival (64).  
 
1.6.2 Pre-treatment and post-treatment levels and association with pCR 
The dynamic expression of immune lymphocytic infiltration has been evaluated in pre- and 
post-treatment samples of BC patients treated with neoadjuvant chemotherapy (NACT). In a 
large series of 716 patients with paired pre- and post-treatment samples, TIL levels significantly 
decreased after completion of chemotherapy (pre-NACT mean TILs= 24.1% versus post-
NACT mean TILs=13.0%) and this decrease was associated with high pCR rates (65).  In 
examined patient samples from the SWOG S0800 trial, TILs levels significantly decreased in 
the pCR cases after treatment while remained similar with the pre-treatment levels in patients 
the residual disease; no association with survival outcomes was observed (66). Of note, in 
HR+/HER2- patients, sTILs and CD8+ T-cells were significantly decreased in post-treatment 
samples while gene expression profiling revealed that immune gene-based cell subpopulations 
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corresponding T-regs was also downregulated (67). Regarding lymphocytic subpopulations, 
significantly decreased in CD4+, CD20+ and CD68+ levels were observed in post-treatment 
samples. High decrease of CD4+ and CD20+ and CD3+ cells were associated with pCR and 
also with better survival outcomes (especially for the CD3+) (68). 
1.6.3 Residual disease after neoadjuvant chemotherapy 
Given that non-pCR BC patients treated with neoadjuvant therapy are associated with worse 
prognosis  (13), the evaluation of TILs infiltration in the residual disease and its effect on long-
term outcomes represent an emerging research topic of high interest. 
In TNBC, a recent study derived from four patient cohorts (n=375) has shown that higher 
residual disease TILs were significantly correlated to improved RFS and OS (69) and similar 
results have been also derived from another retrospective multicenter study (n=278) (70). When 
different immune cell populations were evaluated in the residual tumors of TNBC patients, 
high CD8+ TIL levels and a high CD8/FOXP3 ratio significantly correlated with prolongs 
recurrence-free and breast cancer-specific survival (71).  
Apart from the evaluation of stromal TILs in the residual disease, enrichment of immune-
related gene signatures correlated with favorable prognosis mainly in the TNBC subtype (72, 
73). These findings indicate TILs as a new surrogate endpoint, underscores the need for 
evaluating on-treatment immune infiltration and can improve prognostication in non-pCR 
TNBC patients after neoadjuvant chemotherapy (74). Indeed, the reported results of the 
CREATE-X randomized phase 3 trial in patients who did not achieve pCR, indicated that 
administration of adjuvant capecitabine improved both 5-year DFS (74.1% vs 67.6%; HR: 
0.70, 95% CI 0.53–0.92, p=0.01) and OS (89.2% vs 83.6%; HR: 0.59, 95% CI 0.39–0.90, 
p=0.01) as compared to the control group, and especially in the TNBC subgroup (75). 
In contrast, in HER2+ BC treated with neoadjuvant chemotherapy (+/- trastuzumab), high TIL 
levels in with residual disease were significantly independently associated with worse disease-
free survival and higher residual tumor burden (76), while an increase of FOXP3+ TILs 
indicative of an immunosuppressive phenotype has been described in HER2+ residual disease 
(77).  
The predictive capacity of TILs has been also evaluated in combination with other indicators 
of residual disease such as residual cancer burden (RCB), which represents a combined 
continuous index of primary tumor (size and cellularity) and nodal metastases (number and 
size) measurements (78). Of note, Asano and colleagues have shown that combination of RCB 
with high TILs was a significant independent marker of reduced risk of recurrence in all BC 
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subtypes (79) while in another study it was demonstrated that TILs can also add prognostic 
information to RCB (69, 78). 
 
1.7 Immune cell subpopulations and prognostic correlations in breast cancer  
Given that all mononuclear cells are included in the scoring of TILs in BC tissue stained with 
hematoxylin-eosin (H&E) (46, 56), the role of the specific immune cell subpopulations needs 
to be better clarified. TILs include components of both innate immunity e.g macrophages, 
natural-killer (NK) cells, dendritic cells (DC) and myeloid-derived suppressor cells (MDSCs) 
and also adaptive immunity e.g.  CD8+ and CD4+ T-cells, T-regs. Each of these major 
subpopulations within tumor immune microenvironment (80) can influence patient outcomes 
(81). It has been described earlier that increased inflammatory/immune infiltrate was correlated 
with improved survival outcomes in more than half of the identified reports (82). Specifically:  
Cytotoxic T Lymphocytes (CTLs): The prognostic role of CD8+ cytotoxic tumor-infiltrating 
lymphocytes has been demonstrated in two large retrospective primary breast cancer studies 
(n1=8,978 and n2=1,334) (83, 84). The presence of CD8+ TILs was significantly independently 
correlated with improved survival outcomes in both cohorts. Moreover, this effect was seen in 
the ER-negative/basal-like and HER2-enriched tumors but not in the luminal subtype. 
T-regulatory cells: This type of T-cells is immunohistochemically characterized by the nuclear 
expression of Forkhead box P3 (FoxP3) and is generally considered as immunosuppressive and 
linked to tumor progression (85). In a large retrospective analysis of three studies (n=5239), 
FoXP3+ cells were not correlated with breast cancer-specific survival  (83) whereas in another 
large meta-analysis (n=8,666), patients with high FoXP3+ TILs were associated with worse 
overall survival (86). Of note, the CD8/FoxP3 ratio represents an immune activation parameter 
and a higher ratio has been linked to better survival in ER-negative BC patients (87). 
CD4+ T-cells subsets: Apart from the T-regs, CD4+ T-helper subsets include T-helper 1 (Th1) 
Th2, Th17 and follicular helper T-cells (Tfh) (88). Th1 and Tfh have been associated with 
favorable DFS and OS in BC patients (89). In contrast Th2 and Th17 have been mostly 
correlated to immune escape and poorer prognosis (90).   
Myeloid-derived suppressor cells: MDSCs denote a heterogeneous population of myeloid cells 
(CD33+ and CD11b+) which promote an immunosuppressive microenvironment, tumor 
progression and metastatic spread. In BC, higher levels of MDSCs (circulating or infiltrating) 
were correlated to poorer survival and low pCR rates (91-93).  
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B-cells: Tumor-infiltrating B-cells have been characterized as a cell type linked to functional 
humoral immune response (94) and there are also present in breast cancer tertiary-lymphoid 
centers (TLS) (95) . B-cell expression (CD20+ cells) has been correlated with favorable 
outcome (96) but since it has dual pro- and anti-tumorigenic properties (97), a B-regulatory cell 
phenotype has been recently recognized to be an adverse prognostic factor combined with T-
regs in BC patients (98).  
Tumor-associated macrophages (TAMs):  This heterogeneous immune cell subpopulation 
plays a major role in immune evasion, angiogenesis and metastasis and it is roughly divided in 
two distinct subtypes: the “M1-like” and “M2-like” macrophages which have anti- and pro-
tumoral properties respectively (99). Breast cancer patients with high TAM density (mostly of 
CD68+ and CD163+ macrophages) were associated with worse prognosis as demonstrated in 
large meta-analysis of sixteen studies (HR=1.50; 95% CI 1.20-1.88 and HR=2.22; 95% CI 
1.71-2.89 for OS and DFS, respectively) (100). 
 
1.8 TILs evaluation methodology and future perspectives  
TILs in early BC are currently detected under light microscope in H&E stained tissue sections 
according to the established guidelines by the International TILs Working Group (46), which 
were adapted for TILs evaluation in Ductal Carcinoma In Situ (DCIS) and in metastatic tumor 
deposits (56) and also further updated for the TILs scoring in residual disease after NAT (101). 
According to these recommendations general scoring is performed for lymphocytes and plasma 
cells, excluding polymorphonuclear lymphocytes. TILs should be scored preferably in whole 
tissue sections (4-5um of thickness) as compared to biopsies and the average assessment should 
be done in order the whole tumor area to be covered, instead of focusing on hotspots. The 
scoring should include only sTILs and should be reported as the percentage (%) of the stromal 
compartment covered by TILs. TILs in the stroma area should be in direct contact with breast 
carcinoma cells. 
However, no optimal cut-off for TILs abundance has been formally established and needs to 
be addressed along with the investigation of their clinical utility. Better understanding may lead 
to integration of TILs as biomarkers in routine clinical care though the development of 
prognostic risk models or as tools for better patient selection in future immunotherapy clinical 
trials.  
Of note, the latest advances in artificial intelligence and digital pathology (102, 103) could also 
lead to the optimization and standardization of TILs evaluation in BC, thus increasing 
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reproducibility and accuracy of scoring (104).  In a recent work, automated TILs evaluation 
(eTILS%) in TNBC using an open source algorithm launched a new method for lymphocytic 
infiltration assessment (105). High eTILs% score generated using the algorithm previously 
reported in melanoma (106) was independently associated with improved OS in four TNBC 
patient datasets (105). 
Furthermore, multiplex imaging methods (107, 108) could provide a better insight in the TIME 
composition and in how the different lymphocytic and macrophage subpopulations and 
interactions can influence tumor biology, patient survival outcomes.  
 
1.9 The role of immune-related genes and signatures as biomarkers in breast cancer  
Moving forward from the morphologic evaluation of TILs to gene expression-based profiling, 
relevant immune signatures have been investigated as an alternative way of evaluating the 
immune microenvironment of the tumor  and as potential prognostic and predictive biomarkers 
in BC.  
A variety of in silico computational approaches and bioinformatic tools have been developed 
(109) for the deconvolution of tumor immune microenvironment including: i) CIBERSORT 
(Cell type identification by estimating relative subsets of RNA transcripts) (for the vigorous 
enumeration of 22 hematopoetic subsets from RNA mixtures; LM22 gene signature matrix) 
(110) , ii) ESTIMATE (Estimation of STromal and Immune cells in MAlignant Tumor tissues 
using Expression data) (111), iii) MCP-counter (Microenvironment Cell Populations counter) 
(quantification and estimation of the absolute abundance of immune and stromal cell 
populations based on gene expression) (112), iv) TIMER (Tumor Immune Estimation 
Rescource; estimation of the abundance of six immune cell types, namely B cells, CD4 T cells, 
CD8 T cells, neutrophils, macrophages and dendritic cell in TME) (113), v) xCELL (novel 
gene signature-based method for determination of 64 immune and stromal cell types) (114) and 
vi) the general tool Gene Set Enrichment Analysis (GSEA)/ Gene Ontology (GO) Enrichment 
analysis (differential genome-wide expression profiles; can be used for TIME evaluation with 
a focus on immune pathways) (115). For detailed description of the tools used in the thesis see 
below (Patients and methods: Bioinformatic tools for in silico analysis of immune cell 
subpopulations and tumor microenvironment). 
Additionally, the emerging role of single-cell sequencing approaches could be utilized for the 
comprehensive characterization immune cell composition in BC (116). These new 
technologies can be valuable tools for the better understanding of TIME and for the design of 
novel immunotherapies in (breast) cancer (117, 118). 
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The advances in gene expression profiling and RNA-sequencing have led to the emergence of 
immune response-related genes as tools for grasping the complexity of tumor-immune 
interactions as well as their potential as biomarkers across tumor types (119, 120). 
It has been described that immune-related gene signatures can predict increased pCR rates in 
BC subtypes in the neoadjuvant setting. In the GeparSixto neoadjuvant trial, a 12-gene 
immune-relevant signature including T-cell, B-cell chemokine and immune checkpoint-related 
mRNA markers has been derived from 481 breast tumors and differentially correlated to sTILs 
levels. Of note, all the immune-related genes were significantly associated with increased pCR, 
while at the single gene level the highest odds ratio was observed for PD-L1 gene which also 
represented an independent predictor of pCR (multivariate model included also sTILs). Some 
genes were also correlated with prediction of carboplatin response (48). Similarly, the favorable 
effect of enriched immune-related gene signatures as predictive markers to neoadjuvant 
chemotherapy has been also described by Sota and colleagues who developed an immune-
related 23-gene signature which predicted pCR irrespective of the NACT regimens (121). 
Ignatiadis et al, also reported that high expression levels of T cell-related immune signatures 
can predict response to neoadjuvant anthracycline +/- taxane -based chemotherapy (122). 
Similarly, it has been recently described in a secondary analysis of the GeparSepto trial that 
mRNA-based immune-cell activity (immune “hot/warm” patients) can independently predict 
neoadjuvant chemotherapy response and long-term prognosis in HER2-negative BC patients 
(123).  Moreover, in the HER2+ patient population, high expression levels of T-cell-related 
immune signatures were predictive of response to neoadjuvant lapatinib +/- trastuzumab in the 
NeoALTTO trial (124). 
In the adjuvant setting, two large randomized phase III trial have reported the association of 
immune-related genes to anti-HER2 antibody treatment effect. In the N9831 trial, early BC 
patients with an enriched expression of a 14-gene immune signature had significant benefit 
from the addition of adjuvant trastuzumab (125). Furthermore, in an additional translational 
sub-study of the NSABP-31, patients with high expression of a surrogate gene expression 
signature of TILs (TILs-related genes) correlated to adjuvant trastuzumab benefit when it is 
added to doxorubicin-cyclophosphamide + paclitaxel chemotherapeutic combination (126).  
Taken together, a variety of evaluation methods for immune cell infiltrate have been 
comprehensively investigated in a recent study in breast cancer (127). The approaches included 
sTILs H&E and IHC staining of immune cell markers and manual/digital assessment in whole 
tissue sections as well as in TMAs. Transcriptomic and methylomic-based approaches were 
also examined and important differences were observed in the different methods for the 
evaluation of overall immune infiltration.  
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1.10 The Programmed Death-1/Ligand-1 (PD-1/PD-L1) signaling axis in cancer  
Programmed Death 1 (PD-1, CD279) is a 40kDa cell surface protein (transmembrane type 1) 
and a member of CD28/CTLA-4 family and immunoglobin superfamily. It is encoded by 
PDCD1 gene located on 2q37.3 chromosome (128).  PD-1 is mainly expressed on activated T 
cells but it can also be expressed in other cells such as B cells, macrophages, DC and NK cells 
(80, 128-131). Programmed Death Ligand 1 (PD-L1, B7-H1, CD274) and PD-L2 (B7-DC, 
CD273) represent the two ligands of PD-1 and belong to the B7 family of immune-regulatory 
proteins. PD-L1 is mainly expressed on the surface of tumor cells but it can be also present on 
various cell types including T cells, B cells, DC, macrophages, mesenchymal stem cells and 
endothelial cells (132, 133). PD-L1 transmembrane type 1 protein (33kDa) consists of an 
extracellular immunoglobulin V-like and C-like domains, a hydrophobic transmembrane 
region, and a 30-amino acid cytoplasmic tail. PD-L2 is almost exclusively expressed on APC. 
PD-L1 and PD-L2 are encoded by CD274 and PDCD1LG2 genes, respectively, located on 
chromosome 9p.24.1 PD-1/PD-L1 axis is considered as an “immune checkpoint” with crucial 
impact on autoimmunity (by suppression of cytokine production and T-cell repertoire) , chronic 
infection and anti-tumor immune response (134). A two signal-activation model is required for 
T-cell: i) APC and the MHC presented on the surface from T-cell receptor (TCR) (first signal) 
for antigen recognition and ii) co-stimulatory interaction between CD28 (T-cell surface) and 
CD80 (B7.1) or CD86 (B7.2) (APC surface) (second signal) (135, 136). Therefore, the 
engagement of PD-1 with its ligands PD-L1 or PD-L2 preceding the impairment of effective 
cytotoxic T cell action and proliferation, increased differentiation of T-regs and thus immune 
cell dysfunction (137) (Figure 2). Blocking the PD-1/PD-L1 signaling axis with monoclonal 
antibodies can reverse the ineffective anti-tumor immunity and this has proved to be an 





Figure 2.  PD-L1/PD-1 signaling axis and interactions among tumors cells, T-cells and 
antigen-presenting cells  
 
 
1.11 PD-L1/PD-1 regulation in cancer 
Despite the success of immunotherapy in clinical practice, the elucidation of tumor-immune 
system interplay complexity and underlying mechanisms which govern PD-L1 expression is 
of high importance. The biology of PD-L1 regulation is complex and includes genetic, 
transcriptional, signaling pathway, post-transcriptional as well as post-translational regulatory 
networks (Figure 3) (140). Further understanding of PD-L1 regulation may lead to the 
introduction of combinational treatments of immunotherapy and targeted therapies, already 
available for clinical implementation.  
The genetic basis of PD-L1 expression has been described and varies among various cancer 
types. One of the most common copy number alterations is amplification of PD-L1 locus which 
may lead to elevated PD-L1 protein levels. PD-L1 amplification was most prevalent in 
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Hodgkin’s lymphoma and those patients highly responded to immune checkpoint blockade 
therapy (141). Therefore, given the challenges on PD-L1 protein evaluation, PD-L1 
amplification could serve as alternative for identifying patients gaining the most benefit of 
immunotherapy. In a large retrospective study including 118,187 solid tumor samples from 
more than 100 types, PD-L1 amplification was a rare event since it was detected in only 0.7% 
of the cases (1.9% among breast tumors) and therefore its clinical usefulness remains 
questionable (142).  
A number of oncogenic signaling pathways including Janus Kinase (JAK)/Signal activation of 
Transcription (STAT), RAS/extracellular signal-regulated kinase (ERK) and/or 
phosphatidylinositol 3-kinase  (PI3K)/AKT/mechanistic Target Of Rapamycin (mTOR) 
contribute to the regulation of PD-L1 expression and therefore modulate the anti-tumor 
immune response (143). At the transcriptional level, a lot of factors can regulate PD-L1 
expression either directly via binding to the gene promoter or indirectly by regulating other 
pathways or epigenetic modifiers. Such transcription factors include signal activation of 
transcription 3 (STAT3), hypoxia inducible factor 1 (HIF-1), p53, Myc, nuclear factor-kappa 
beta (NF-κΒ) and activator protein 1 (AP-1). Especially for STAT3, a major oncogene which 
has a role in several cellular processes (144), it has been recognized to play key role in the 
regulation of antitumor immunity. Its interplay with various types of immune cells, cytokines, 
immune checkpoint molecules and other intrinsic pathways can shape a specific (pro- or anti-) 
inflammatory/tumorigenic microenvironment and lead to tumor escape from 
immunosurveillance (145).  
PD-L1 is also prone to regulation at the post-transcriptional level and post-translational level 
with several microRNAs (miRNA) ubiquitination and glycosylation processes to influence the 
regulation of PD-L1 (140). Nevertheless, the exact mechanisms of PD-L1 regulation represent 
an area of intensive research and could provide the biological rationale for novel therapeutic 
strategies. 
PD-1 expression is also regulated by a variety of factors in cancer. Signal transduction mediated 
by cytokines (i.e. IL-2. IL-7, IL-15, IL-21) can enhance PD-1 expression on T-cells (146). 
Moreover, different mechanisms can also mediate an effect on PDCD1 gene promoter either 
through the direct impact of transcription factors such as the nuclear factor of activated T-cells, 
cytoplasmic 1 (NFATc1) (147), NF-kb/p65 and Forkhead box O1 (FoxO1) or through IL-
mediated induction of factors which can enhance gene promoter activity (IL-6 – STAT3, IL-





Figure 3. PD-L1 regulation including genetic, transcriptional and post-
transciptional/translational underlying mechanisms (Zerdes et al., Oncogene 2018) 
 
 
1.12 PD-L1 expression in breast cancer: prognostic and predictive implications  
The role of the PD-L1 expression as prognostic and predictive biomarker has been extensively 
investigated in BC. Given that PD-L1 can be expressed in both tumor and immune cells, 
prognosis and prediction of various treatments mostly depend on the cell of origin, type of 
tissue (tissue microarrays or whole-tissue sections), BC subtype as well as the disease setting 
(148). Some previous reports have shown that PD-L1 expression in tumor cells was a negative 
prognostic factor (149, 150) while some others have demonstrated the correlation of PD-L1 
expression with better prognosis in patients with early breast cancer (151, 152). Given that PD-
L1 is considered as a co-inhibitory marker leading to impaired anti-tumor immune response 
this favorable outcome correlation seems indeed to be paradoxical. However, a positive 
correlation between PD-L1 expression and increased T cell infiltration was reported in a 
number of studies (153-156), indicating that PD-L1 may represent a surrogate marker/ indicator 
of immune cell infiltration and activation -which has been related to improved prognosis- rather 
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than a marker of exhausted T-cells. A possible explanation would involve interferon-gamma 
(IFN-γ) secreted by TILs which can play a dual role: a) minimize the immune cell infiltration 
once this is reactive and b) lead to the induction of PD-L1 expression. This procedure is called 
“adaptive resistance” and indicates a beneficial impact of a pre-existing inflamed immune 
microenvironment with high -but inhibited- immune cell infiltration (157-159). PD-L1 tumor 
cell expression has been also correlated with other clinicopathologic characteristics such ER 
and HER2 negativity, high Ki67, larger tumor size, grade 3 tumors (153). 
Hence, many of the previous studies have reported conflicting results and therefore both the 
role of PD-L1 as a prognostic biomarker in early BC and the overall positivity rates (overall 
and within subtypes) still remain inconclusive. Furthermore, the meta-analyses that have been 
previously performed in the topic included a small number of studies and suffer from 
methodological limitations. A comprehensive analysis on the role of PD-L1 as a prognostic 
biomarker in early BC is presented in this doctoral thesis (see paper I)(160). 
Besides, in order to overcome the analytical and technical difficulties of protein detection, PD-
L1 gene expression has been emerged as an alternative approach. Its role as a biomarker needs 
to be further elucidated, since it has been associated with improved prognosis in early BC 
patients especially in basal-like subtype (156, 161).  
However, the improved prognostication conferred by PD-L1 expression might be attributed to 
the possible predictive role that PD-L1 expression could have in patients receiving 
chemotherapy, since we have demonstrated (57, 162) (see also paper V hereunder) that 
immune-related gene signatures, including PD-L1, are drivers of chemosensitivity. This 
hypothesis needs to be tested in a prospective or prospective-retrospective randomized manner 
and in different disease settings.  Furthermore, the predictive value of PD-L1 and the concept 
of immune-mediated chemosensitivity seems to vary according to the disease setting and BC 
subtype. As an example, in subgroup analyses of two large randomized immune checkpoint 
blockade clinical trials, IMPassion130 and KEYNOTE-119, the effect on PFS or OS in the 
chemotherapy-only arm was the same irrespective PD-L1 status in the locally advanced or 
metastatic TNBC disease. (163, 164).  
In the neoadjuvant setting, a recent meta-analysis reported that pre-treatment PD-L1 expression 
was associated with increased pCR rates but no subgroup analysis regarding specific subtypes 
was performed (165). The association between baseline PD-L1 and higher pCR rates has been 
also demonstrated in prospective-retrospective analysis of two trials on anthracycline-based 
NACT +/- bevacizumab (67, 166). Moreover, PD-L1 TILs expression predicted response to 
neoadjuvant trastuzumab emtansine (T-DM1) in the translational study of the phase II 
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HR+/HER2+ WSG-ADAPT trial (167). Of note, PD-L1 mRNA upregulation was correlated 
with increased pCR rates in a large retrospective cohort of anthracycline-based NACT (161). 
Given that PD-L1 expression in immune cells seems to represent a promising favorable 
prognostic factor in early breast cancer (see paper I), its expression in specific immune cell 
subpopulations needs to be further explored using spatial pattern approaches (168, 169). 
 
 
1.13 PD-L1 testing in (breast) cancer: analytical validity, performance and variation in 
assessment methodologies  
The controversial results on the prognostic value of PD-L1 expression in BC, highlight the lack 
of common evaluation guidelines for the use of PD-L1 as biomarker. Indeed, in the previous 
reports a plethora of different immunohistochemical antibodies and clones (i.e Ventana: clone 
SP142, clone SP263; Dako: clone 28-8, clone 22C3), staining platforms, positivity cut-off 
values and scoring methods have been described according to the compartment of expression, 
thus hindering the interpretation of the results and implementation in clinical routine. 
Moreover, PD-L1 evaluation in tissue microarrays and whole tissue sections among the studies 
underscores the presence of substantial expression heterogeneity.  
Following the paradigm of BluePrint projects in lung cancer (170, 171) and other similar 
approaches (172-174), few studies have directly compared various PD-L1 antibodies in BC  
(175-177).  In a recent multicenter study comparing four clinical developed anti-PD-L1 
antibodies in whole tissue sections of TNBC, the PD-L1 immune cell positivity expression 
(≥1%) was significantly higher for SP263 and similar among the other clones with strong 
reproducibility and concordance (178). Different antibody clones and scoring systems have 
been evaluated in another retrospective study including 196 TNBC patients. Similar analytical 
performance was observed across SP263, 22C3 and 28-8, clones for both tumor and immune 
cell expression, while lower scores were noted with SP142 (179).  
Moreover, the performance of the only approved companion diagnostic PD-L1 Ventana clone 
SP142 antibody (see below Biomarkers of immune checkpoint blockade in (breast) cancer and 
mechanisms of resistance) has been also investigated in a large retrospective cohort (n=498) of 
TNBC patients. 46% of the patients were PD-L1 IC positive with heterogeneous staining and 
correlated with stromal TILs and improved IDFS and OS in the univariate analyses (180).    
There is a need of PD-L1 antibody and scoring harmonization (181) for the proper selection of 
candidate BC patients for treatment with immune checkpoint inhibitors. The different PD-L1 
scoring systems, antibody clones and therapeutic monoclonal antibodies are summarized in 
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Table 1 and challenges are also described below in detail. Scoring methodology consensus and 
digital pathology/image analysis may provide -as also in the case of TILs- higher accuracy and 
reproducibility in the evaluation of PD-L1 (182, 183).
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Table 1. Comparison of different PD-L1 scoring methods, antibody clones, positivity cut-offs, and correspondence to immune checkpoint inhibitors  
Score PD-L1 scoring description PD-L1 antibody clone 
/Company 
Cut-off Checkpoint inhibitor Trial 
ICA Percentage of tumor area occupied by PD-L1 
stained positive immune cells  or 
PD-L1+immune cells / tumor area         
SP142 / Ventana 
(companion diagnostic 
approved by FDA) 
≥1% Atezolizumab  IMPassion130 
KATE-2 
 
CPS Positive tumor or immune cells as percentage of 
all tumor cells or 
PD-L1+immune cells + PD-L1+tumor cells / 
tumor cells         
22C3 / Dako KN-522  ≥1 and ≥10 
KN-119 ≥1 and ≥10 
Pembrolizumab KEYNOTE-522                
KEYNOTE-119              
KEYNOTE-173           
KEYNOTE-086             
PANACEA                             
TONIC 
TPS Proportion of PD-L1 stained tumor cells over 
the total number of tumor cells or 
PD-L1+tumor cells / tumor cells         
SP263 / Ventana 
73-3 / Dako 
28-8 / Dako 
≥1% 
( ≥5% for any staining 
and  ≥25% for 
moderate/high staining) 
Durvalumab GeparNuevo 
ICIC% Proportion of PD-L1 stained tumor cells over 
the total number of immune cells or 
    PD-L1+ immune cells / immune cells         
Avelumab JAVELIN 
 
  21 
1.14 PD-1 expression in early breast cancer  
The expression patterns as well as the prognostic value of PD-1 have not been fully elucidated 
with results remaining inconclusive due to the lack of standardized methodology in the 
assessment and variation of study populations. Some previous studies have demonstrated that 
high PD-1 expression on TILs correlated to worse prognosis (184, 185) while others 
demonstrated PD-1 was associated with improved survival in TNBC (186-188) especially 
when expressed in CD8+ T-cells (187).  Whether PD-1 gene expression could represent a 
prognostic marker is yet unclear, even though a report demonstrated promising results in the 
triple-negative subtype (187), and it merits further investigation in the different BC settings. A 
comprehensive analysis on the role of PD-1 as a prognostic biomarker in early breast cancer is 
presented in this doctoral thesis (see paper IV). 
 
1.15 Temporal expression of PD-L1 and PD-1 and prognostic implications in breast 
cancer  
1.15.1 PD-L1/PD-1 expression in primary tumors and in paired metastases  
Another topic of interest is the dynamic evaluation of expression of PD-L1 and PD-1 both 
spatially and temporally. Even though the extent of intra-tumoral heterogeneity of PD-L1 
expression and its potential clinical implications have not been evaluated, a growing body of 
literature is focusing on the expression of these immune checkpoints in the metastatic setting 
(both lymph node and distant metastases).  In a recent study evaluating PD-L1 expression in 
primary and paired metastatic breast tumors (n=76), both protein and gene expression levels 
were lower in the metastatic sites (63). Other reports have demonstrated higher levels of PD-
L1 expression in the secondary as compared to primary lesions (189, 190). High discrepancies 
of PD-L1 expression were also noted between primary tumors and distant metastases (28.5% 
for PD-L1 on tumor and 40.8% for PD-L1 on immune cells), although there was no statistically 
significant association with survival outcomes (191). Of note in TNBC, PD-L1 expression 
(immune cells) in distant metastasis did not confer any prognostic value (62) whereas PD-L1 
expression in lymph node metastases was correlated to worse disease-free survival (192). 
On the other hand, few reports have evaluated the expression of PD-1 in primary and in 
matched metastatic patient samples. Gene expression of PD-1 was lower in BC metastases 
versus primary tumors (63). In terms of prognosis, patients with PD-1 protein expression on 
TILs (23% of the cases) in BC brain metastases were proven to independently correlate with a 
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favorable outcome (64) while in a recent study with high discordance between primary and 
matched distant metastases (50% of the patients), association with prognosis was shown (191). 
Therefore, the additional information and clinical relevance that immune checkpoints can 
provide remains unknown and more research is needed towards further understanding of the 
immune microenvironment in BC metastases, given the effect and recent approval of the anti-
PD-L1 antibody atezolizumab in patients with triple-negative advanced or metastatic BC. Of 
note, a post hoc analysis of the IMPassion130 study compared the performance of various PD-
L1 IHC assays and demonstrated that PD-L1 expression on immune cells (clone SP142, 
Ventana, Roche) was higher in the primary as compared to the metastatic tissue (44% versus 
36%, p=0.014) and associated with improved PFS and OS in the atezolizumab + nab-paclitaxel 
arm. Among the different metastatic anatomical locations, PD-L1 was mostly expressed on 
lymph nodes (51%) and the skin (48%) (193),  
 
1.15.2 PD-L1 / PD-1 expression in the neoadjuvant setting  
1.15.2.1 Pre-treatment and post-treatment levels and association with pCR 
Given that in the neoadjuvant setting, pre-treatment PD-L1 evaluation or post-treatment was 
found to be associated with increased rates of pCR in most of the previous studies (194, 195), 
some recent reports have focused on the evaluation of PD-L1 expression in both the pre- and 
post-treatment BC samples. In the analysis of 60 patient samples from the SWOG S0800 
neoadjuvant trial, levels of PD-L1 protein (tumor or stromal cell) and mRNA expression did 
not significantly change between pre- and post-treament or between pCR and non-pCR patients 
(66). In HR+/HER2- breast cancer patients (n=96), there was a trend towards significant 
decrease in the PD-L1 expression in tumor cells but no association with RCB (67). 
1.15.2.2 Breast cancer residual disease 
Data on the expression of PD-L1 in the residual disease and its role in the long-term outcomes 
are scarce. In a study including 309 breast cancer patients with residual disease following 
neoadjuvant chemotherapy, high PD-L1 expression was independently associated with worse 
RFS and OS, especially in the triple-negative disease. Moreover, combined PD-L1 high/low 
TILs (CD8+) was also a factor of adverse outcome (196).  
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1.16 Effect of chemotherapy on PD-L1/PD-1 axis and immune response  
Both preclinical data on different regimens (140) and also clinical data support the effect of 
chemotherapy on immune response and on the PD-L1/PD-1 immune checkpoint in particular 
(197). The dynamic expression of PD-L1 and changes in immune infiltration (see above 
temporal expression) might be explained by the immunogenic cell death induces by cytotoxic 
chemotherapy and that subsequently enables T-cell responses against dying tumor cells (198). 
The impact of PD-L1 expression upon modulation by NACT in long-term patient outcomes, 
still remains unclear, even though it can predict pCR. Thus, clinical trials combining 
chemotherapy and immunotherapy in the neoadjuvant setting as well as post-neoadjuvant 
chemotherapy in patients who did not achieve pCR are ongoing. 
 
1.17 Immune checkpoint blockade and predictive biomarkers in (breast) cancer  
As previously described, immune checkpoints such as PD-1 and its ligand PD-L1 as well as 
cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) have been recognized as inhibitory 
molecules which cause impaired immune response against cancer cells. Further understanding 
of their role in antitumor immunity has paved the way for the development of immune 
checkpoint inhibitors, thus revolutionizing the management of a wide spectrum of 
malignancies (199) and leading to the award of the 2018 Nobel Prize in Physiology or Medicine 
(https://www.nobelprize.org/prizes/medicine/2018/prize-announcement/). 
In a recent network meta-analysis including 11,379 patients (though breast cancer was not 
included) in 19 randomized clinical trials evaluating the differences between treatment with 
anti-PD-L1 and anti-PD-1 antibodies, it was shown that anti-PD-1 demonstrated superior OS 
and PFS as compared to anti-PD-L1. Safety profiles were similar between the two (200). 
 
1.17.1 Immune checkpoint inhibition in breast cancer 
In contrast with the plethora of randomized clinical trials published in various tumor types, 
prospective randomized data in BC using immune checkpoint inhibitors currently come from 
a few major clinical trials (201) which are summarized in Table 2. 
Metastatic setting: The IMPassion130 is the only randomized phase 3 trial which demonstrated 
benefit from the combination of atezolizumab and nab-paclitaxel compared to nab-paclitaxel 
alone in patients with triple-negative metastatic BC and PD-L1 immune cell positivity (163, 
202). In the intention-to-treat population (ITT) (n=902), median PFS (7.2 versus 5.5 months) 
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but not OS (21.3 versus 17.6 months, non-significant) was statistically significantly prolonged 
with the addition of atezolizumab to chemotherapy. In the PD-L1 immune cell-positive cases 
treated with atezolizumab, median PFS remained improved (7.5 versus 5.5 months; HR= 0.62, 
95% CI 0.49-0.78, p<0.001) and importantly OS was also prolonged (25 versus 18 months; 
HR=0.71, 95% CI 0.54-0.94) in this patient subgroup as shown in the updated overall survival 
data (202). Based on this study results, Federal Food and Drug Administration (FDA) has 
approved the use of the first immune checkpoint inhibitor in BC patients in 2019 (203).  
Apart from the combination of immune checkpoint inhibitors with chemotherapy, recent data 
from pembrolizumab monotherapy in patients with metastatic TNBC treated with prior 
chemotherapy, have been reported in the KEYNOTE-086 phase 2 study. In cohorts A (n=170, 
PD-L1 unselected patients) and B (n=84, only PD-L1 positive tumors included), the objective 
response rates (ORR) were 5.3% and 21.4%, respectively (204, 205). On the other hand, the 
phase 3 KEYNOTE-119 did not meet its primary endpoint for improved OS in the 
pembrolizumab arm as compared to chemotherapy in metastatic TNBC (164).   
Moreover, according to the preliminary press release of the randomized phase III KEYNOTE-
355 trial (ClinicalTrials.gov, NCT02819518), the addition of pembrolizumab to chemotherapy 
indicated statistically significantly improved PFS in PD-L1+ (CPS ≥10) metastatic TNBC 
patients as compared to chemotherapy alone, with the announcement of the results to be 
awaited (news release by Kenilworth, NJ: Merck;  https://bit.ly/2HtT4rj).    
Finally, in the whole cohort of 67 TNBC patients receiving nivolumab in combination with 
chemotherapy or radiotherapy, the ORR was 20% with the majority of responses observed in 
the cisplatin and doxorubicin arms, as demonstrated in the adaptive phase II TONIC trial (206). 
Of note, the increased TILs, PD-1 (in immune cells) and immune-related genes in responders 
versus non-responders indicated that treatment can induce an inflamed tumor 
microenvironment which can further sensitize patients to PD-1 blockade.  
 
Neoadjuvant setting: In the phase 3 randomized trial KEYNOTE-522, neoadjuvant 
pembrolizumab in combination with chemotherapy resulted in significantly increased pCR 
rates as compared to chemotherapy alone (64.8% versus 51.2%, respectively), regardless of 
PD-L1 status (207). Furthermore, addition of pembrolizumab to chemotherapy resulted in a 
pCR rate of 60% (range 30-80%) and prolonged 12-month EFS (80-100%) across all cohorts 
in the recently reported neoadjuvant KEYNOTE-173  trial (208).  
Recent results from the ongoing open-label, multicenter, adaptively randomized phase 2 I-
SPY2 platform trial including 69 patients randomized to pembrolizumab + chemotherapy 
versus chemotherapy alone (n=181) indicated improved pCR rates for the ICB arm (44% 
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versus 17%  in ERBB2-negative, 30% versus 13% in HR-positive/ERBB2-negative and  60% 
versus 22% in TNBC patients) while achievement of pCR was also predictive of EFS, 
especially for patients in the pembrolizumab arm (209). The addition of the anti-PDL-1 
monoclonal antibody durvalumab to chemotherapy was associated with increased pCR rates 
(61.0% for durvalumab  versus 41.4%, for chemotherapy alone) as shown in the randomized 
phase 2 GeparNuevo trial, comparing durvalumab + chemotherapy versus placebo + 
chemotherapy as a neoadjuvant treatment in TNBC patients (210). 
On the other hand, preliminary results of the NeoTRIPaPDL1 Michelangelo randomized trial 
allocating 280 TNBC patients to neoadjuvant chemotherapy +/- atezolizumab did not result in 
statistically significant differences in pCR rates neither in the intention-to-treat population 
(43.5% for atezolizumab vs 40.8% for chemo only) nor in the PD-L1+ subgroup (51.9% for 
atezolizumab vs 48.0% for chemo only) (211). 
Since, new therapeutic agents that stimulate a sufficient immune effect have been introduced 
into clinical practice, offering a better clinical outcome in cancer patients, several trials using 
anti-PD-1/PD-L1 antibodies (201) as well as other immunomodulatory agents are ongoing in 
different BC disease settings (neoadjuvant, adjuvant, metastatic) with the results to be eagerly 
awaited.  Moreover, combinational strategies including immune checkpoint inhibitors and 
chemotherapy and/or targeted therapy (i.e HER-2 targeted treatment: KATE-2 phase II trial, 
enrolling 202 advanced BC patients to T-DM1 +/- atezolizumab, suggesting a OS benefit for 
PD-L1+ patients in the atezolizumab arm; the PANACEA phase Ib/II trial including 58 
advanced BC patients to single arm pembrolizumab +trastuzumab, demonstrating an objective 
response of 15% among PD-L1+ patients  (212, 213)) have been reported or are currently under 
investigation so as the optimal partner which can enhance immunotherapy efficacy to be 
identified (214, 215).  
 
1.17.2 Biomarkers of immune checkpoint blockade in (breast) cancer  
i. PD-L1 IHC expression  
Research efforts have been made for the identification of reliable predictive biomarkers for 
immune checkpoints inhibitors in various cancer types (140, 216). PD-L1 expression has been 
explored as a predictive marker in a large across cancer meta-analysis (n=4174; BC trials were 
not included) but with inconclusive results (OS HR=0.66, 95% CI 0.59-0.74 for PD-L1+ and  
OS HR=0.80, 95% CI 0.71-0.90 for PD-L1- patients) (217). Its role in BC is also currently 
under investigation (218). In a secondary analysis of IMPassion130, it has been recently 
reported that PD-L1 expression ³1% in immune cells (SP142 clone, Ventana) was a predictor 
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of treatment benefit with the combination of atezolizumab and nab-paclitaxel (219). Similar 
associations were seen between PD-L1 expression in immune cells and both longer ORR and 
overall survival in patients with metastatic TNBC treated with atezolizumab monotherapy 
according to the results of a recent phase 1 study (220).  The relative advantage of the report of 
many studies where PD-L1 expression is correlated with increased efficacy is counterbalanced 
by the observed discrepancies among the current scoring systems and methodologies, antibody 
clones, cut-off values for the various monoclonal antibodies which have been described above 
(Table 1).  Moreover, the spatial heterogeneity of PD-L1 expression further hinders its 
concordant and reproducible evaluation (221).  
Several retrospective results on prospective clinical trials have tried to identify the optimal 
scoring of PD-L1 protein. In a post-hoc analysis (n=614) of the IMPassion130 trial, the 
analytical concordance of three different PD-L1 antibody clones (IC: Ventana SP142, Ventana 
SP263 and CPS: Dako 22C3) was explored.  SP263 and 22C3 identified more patients with 
PD-L1 positivity as compared to SP142. However, in PD-L1+ patients the evaluation with the 
SP142 antibody predicted benefit regardless of positivity or negativity in other antibodies 
(193).  Furthermore, in the other metastatic phase III KEYNOTE-119 study it was shown that 
pembrolizumab correlated with improved efficacy (OS HR=0.58 and PFS HR=0.76) in TNBC 
patients with high PD-L1 expression (CPS³20) and durable responses as compared to 
chemotherapy (164). 
Of note, neoadjuvant pembrolizumab in combination with chemotherapy demonstrated 
statistically significantly increased pCR rates as compared to chemotherapy alone regardless 
of PD-L1 status in TNBC patients as shown in the KEYNOTE-522 study (207). In contrast, 
the neoadjuvant phase Ib KEYNOTE-173 study PD-L1 CPS was significantly correlated with 
improved response to anti-PD-1 pembrolizumab treatment (208). In addition, in the phase II 
GeparNuevo trial, PD-L1 expression in tumor cells was significantly associated with increased 
pCR in the durvalumab arm (210). The predictive capacity PD-L1 IHC expression as 
demonstrated in the context of breast cancer ICB clinical trials is also presented in Table 2. 
 
ii. Tumor-infiltrating lymphocytes 
The role of sTILs expression as predictors of immunotherapy response has been examined in 
the context of some prospective clinical trials (Table 2). In the metastatic setting patients with 
high sTILs numbers were associated with increased response to pembrolizumab as compared 
to chemotherapy both in the KEYNOTE-086 (204, 205) and KEYNOTE-119 (TILs ≥5%; OS 
HR= 0.75 (95% CI, 0.59-0.96)) (222) trials. Moreover, in the biomarker analysis study of 
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IMPassion130 (219), patients with either stromal TILs enrichment or CD8+ tumors 
demonstrated improved PFS and OS only when PD-L1 was simultaneously expressed on 
immune cells. 
Similarly, in the neoadjuvant setting, in the phase Ib KEYNOTE-173 study, higher baseline 
and on-treatment sTILs predicted for increased pCR rates in patients treated with neoadjuvant 
pembrolizumab and chemotherapy (208), while in both KEYNOTE-522 and in GeparNuevo 
higher sTILs predicted for higher pCR rates in both arms (207, 210). 
 
iii. Immune-related genes and signatures  
The role of 18 immune-related gene signatures as predictors to immunotherapy has been 
investigated in TCGA and in two retrospective cohorts (n=177 and n=65) and their expression 
(especially those related T-cell and IFN-γ) were associated with better anti-PD-1 response 
(223-225). Of note, at the single gene level, PD-1 was strongly correlated with immune gene 
signatures, CD8 T cell genes and also with increased anti-PD-1 response rates, thus 
outperforming other markers (224). Since data come from only a single study including very 
few BC patients (n=3), PD-1 mRNA value needs to be further validated in a prospective trial.  
Furthermore, in the translational biomarker sub-study of the prospective GeparNuevo trial, 
IFN-gamma signatures were associated with increased pCR rates in TNBC patients treated 
with the neoadjuvant anti-PD-L1 antibody durvalumab while TILs signature was predictive for 
response in both arms (226).  
 
iv. Tumor mutational burden  
The clinical utility of high tumor mutational burden (TMB) as a predictive biomarker to PD-1 
inhibition has been retrospectively (227) and prospectively validated in a randomized trial, 
demonstrating association with treatment benefit regardless of PD-L1 expression (228). 
Despite its promising capacity as a biomarker, its implementation in routine practice can be 
challenging (229, 230). In breast cancer, continuous TMB significantly independently 







v. Other predictive biomarkers    
In hematological malignancies, PD-L1 gene amplification was correlated with high response 
rates (141), but amplification seems to be a rare event in solid tumors (142). Specific mutations 
and genetic polymorphisms can also influence immune checkpoint treatment response and 
merit further investigation (216). Moreover, a recent large meta-analysis for the investigation 
of predictive biomarkers to immune checkpoint blockade including a variety of methods, 
revealed the promising role of multiplex IHC over previously characterized markers (232). 
Thus, their clinical utility should be further validated in prospective clinical trials and the 
underlying resistance mechanisms and TIME interactions (233) should be thoroughly studied 










Treatment arms Primary endpoint 
(survival outcome, pCR, 
ORR) 
Predictive biomarker analyses 
PD-L1  TILs  
Metastatic/Advanced setting 
IMPassion 130 III 
(TNBC) 
902 Nab-paclitaxel +/- 
atezolizumab 
ITT:  PFS: 7.2 versus 5.5 
months; HR=0.80, 95% 
CI 0.69-0.92, p=0.002);              
OS (last update Jan 2, 
2019): 21 versus 18.7 
months; HR=0.86, 95% 
CI 0.72-1.02; p=0.078) 
Correlation of PD-L1 positive immune 
cell expression (≥1%; SP142 clone) 
with improved PFS (HR 0.62. CI 95% 
0.49-0.78) and OS (HR 0.62, CI 95% 
0.45-0.86)   
 
Correlation of TILs expression levels 
(>10%) with better PFS (HR=0.53, CI 
95% 0.38-0.74) and OS (HR=0.57, CI 
95% 0.35-0.92) in the PD-L1+ 
population (n=460)   
KEYNOTE-086 







Total ORR = 5.3% No significant correlation of PD-L1 
positive tumors (CPS≥1; 22C3 clone) 
with improved ORR (5.7% vs 4.7%) 
and no differences in OS and PFS 
Correlation of high TILs expression 
(>median) with increased response to 
pembrolizumab (ORR 6% vs 2%) and 
higher TILs levels in responders versus 
non-responders (10% vs 5%) 
KEYNOTE-086 






chemotherapy                                  
Total ORR = 21.4% PD-L1 was a predefined marker of 
patient selection 
Correlation of high TILs expression 
(>median 17.5%) with increased 
response to pembrolizumab (ORR 39% 
vs 9%) and higher TILs levels in 









(physician’s choice)  
ITT: No significant 
differences in terms of 
PFS (HR=1.60 CI 95% 
1.33-1.92), OS (HR=0.97  
CI 95% 0.82-1.15) and 
ORR (9.6% vs 10.6%) 
Pembrolizumab correlated with 
improved efficacy OS HR=0.58  CI 
95% 0.38-0.88; and PFS HR=0.76, CI 
95% 0.49-1.18) in TNBC patients only 
with high PD-L1 expression (CPS≥20; 
22C3 clone) 
Correlation of TILs expression levels 
(≥5%) with improved OS (HR= 0.75, 
95% CI 0.59-0.96) only in patients 
treated in the pembrolizumab arm 
TONIC II 
(TNBC) 






ORR: Cisplatin=23% and 
Doxorubicin= 35% 
Correlation of PD-L1 positivity in 
immune cells (≥5%; 22C3 clone) and 
not in tumor cells (≥1%) with better 
ODS and OS 
Responders had significantly higher 
sTILs as compared to non-responders 
(median 12.5% vs 6%) 
Neoadjuvant setting 
KEYNOTE-173  Ib 
(TNBC) 
60 Pembrolizumab + 
chemotherapy 
pCR rates = 60%  (range 
30-80%) and  12-month 
EFS = 80-100% across all 
cohorts 
Correlation of PD-L1 (CPS≥1; 22C3 
clone) with increased pCR 
Significant correlation of higher sTILs 
(baseline and on-treament) with  
increased pCR. 




1174 Pembrolizumab + 
chemotherapy vs 
chemotherapy 




No correlation of PD-L1 (CPS≥1; 
22C3 clone) with pCR 
Correlation of higher sTILs with  
increased pCR 
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Abbreviations: TNBC, triple-negative breast cancer; pCR, pathologic complete response; ORR, objective response rate; ITT, intention-to-treat; PFS, progression-free survival; OS, 
overall survival; HR, hazard ratio; CI, confidence interval; PD-L1, programmed death ligand 1; TILs, tumor-infiltrating lymphocytes; OR, odds ratio; EFS, event-free survival; CPS, 
combined positive score 
 










pCR = 61.0%  for 
durvalumab  versus 
41.4%, for chemotherapy 
and OR = 2.22, 95% CI 
1.06-4.64, P = 0.035 ;  
only in the window 
cohort 
Correlation of PD-L1+ tumor cell 
expression with increased pCR in the 
durvalumab arm 
Correlation of higher sTILs with 




2 AIMS OF THE THESIS  
The overall purpose of this project was to elucidate the expression, regulation and prognostic 
role of immune infiltrate and the Programmed Death-1/ Programmed Death Ligand 1 (PD-
1/PD-L1) checkpoints in early and metastatic BC.  
The specific aims of the study were: 
 
Aim 1: To determine the expression of PD-L1 and PD-1 and their prognostic significance 
in early BC 
Goal 1. To evaluate the protein expression of PD-L1 and PD-1 in tumor and/or immune cells 
and investigate the associations with patient characteristics in different subtypes. 
Goal 2. To investigate the prognostic capacity of PD-L1 and PD-1 gene expression and 
correlation with validated genomic signatures  
 
Aim 2: To characterize the immune infiltrate and explore the prognostic and predictive 
role of its components in early, non-metastatic BC 
Goal 1. To evaluate TILs and other immune cell subtypes (e.g. tumor-associated macrophages) 
and explore their clinical correlations.  
Goal 2. To explore the interplay of immune cell subpopulations with PD-L1 expression using 
indirect in silico information provided by gene expression profiling.  
 
Aim 3: To investigate the mechanisms driving lymphocytic infiltration and PD-L1 
regulation in BC 
Goal 1. To investigate the regulatory mechanisms of PD-L1 in vitro and in vivo 
Goal 2. To explore the impact of PD-L1 regulation and immune cell infiltration in human breast 
tumors 
 
Aim 4: To evaluate the predictive value of immune-related components in metastatic 
breast cancer patients receiving chemotherapy 
Goal 1. To explore the predictive value of immune infiltration to chemotherapy-treated 
metastatic BC patients 
Goal 2. To determine the predictive role of immune-related genes and signatures for the effect 
of chemotherapy in the metastatic BC setting 
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3 PATIENT AND METHODS 
 
3.1 Patient populations 
i. The “Merck” early breast cancer cohort (papers I-IV) 
This patient cohort consisted of 646 women patients diagnosed with primary BC between 1997 
and 2005 in health care region of Stockholm, Sweden that were retrospectively selected using 
the Stockholm-Gotland Breast Cancer Registry. The patient selection was initially based on a 
nested case-control design (cases: patients developing distant metastatic disease; controls: 
patients free from distant disease, matched by adjuvant therapy, age and calendar period at 
diagnosis) but a direct cohort approach was adopted for the scope of the present studies (also 
previously described (234)). Moreover, this cohort included patients (n=59) treated with 
neoadjuvant chemotherapy, who were excluded from further analyses whenever indicated and 
accordingly depicted in the respective flowcharts. Data on clinical and pathological tumor 
characteristics, survival and loco-regional/systemic treatments have been collected and 
previously reported (234). Distant metastasis-free interval (DMFI), defined as the period of 
time from date of diagnosis to the first evidence of distant metastasis (Distant recurrence-free 
interval: DRFI, if death from BC was also included) and overall survival (OS), defined as the 
period of time from date of diagnosis to death of any cause -both censored after 15 years- were 
used as clinical endpoints. The reverse Kaplan–Meier estimate (235) of the median DMFI and 
OS follow-up was 12.4 years (up to December 31, 2012) and 15 years (up until January 10, 
2015), respectively. Furthermore, Biospecimen Reporting for Improved Study Quality 
(BRISQ) criteria for this cohort have been previously published (234). Karolinska Institute’s 
(Stockholm, Sweden) ethics committee has approved all the performed analyses (included in 
papers I - IV) in this patient cohort (Dnr 2006/394-31/3, 2006/1183-31/2 and amendments 
2016/1505-32, 2018/789-32, 2018/790-32) and decided that no additional informed consent 
from the patients was needed. 
 
ii. The Cancer Genome Atlas (TCGA) breast cancer publicly available dataset 
(papers I-IV) 
The Cancer Genome Atlas (TCGA) provisional dataset (236), consisting of 1,100 patients with 
primary breast cancer and available RNA-sequencing (RNA-seq) and clinical-pathological 
data was used for various analyses (included in papers I – IV).  The publicly available data 
generated by the by the TCGA Research Network (https://www.cancer.gov/tcga) were 
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retrieved from cBioportal (237, 238) on November 21st, 2018. OS and Progression-free interval 
(PFI) (defined as the time period from the date of diagnosis to the date of the first occurrence 
of a new tumor event, including progression of the disease, locoregional recurrence, distant 
metastasis, new primary tumor, or death with disease) were used as clinical endpoints as 
recommended; PFI was extracted from the standardized TCGA Pan-Cancer Clinical Data 
Resource dataset (236).  Median follow-up for this cohort (reverse KM estimate) was 2.5 for 
PFI and 2.6 years OS, both censored after 10 years. 
 
iii. The TEX metastatic randomized clinical trial (paper V) 
TEX was a multicenter, randomized phase III trial (ClinicalTrials.gov identifier 
NCT01433614) evaluating the activity of epirubicin and paclitaxel, with or without 
capecitabine, as first line treatment for locally advanced inoperable or metastatic breast cancer 
(239). In total, 287 patients were randomized and tailored treatment doses were used depending 
on the related side effects. A third treatment group with fluorouracil, epirubicin and 
cyclophosphamide (FEC) was closed shortly after the initiation of the study. In light of the 
publication of data regarding trastuzumab efficacy, the initially allowed enrollment of patients 
with HER2 positive disease was discontinued. For the translational part of this study see below 
(paragraph: GEP data derived from original study cohorts). Radiological tumor assessments 
were performed according to the protocol after every third 3-week chemotherapy cycle and 
evaluated according to the Response Evaluation Criteria In Solid Tumors (RECIST) version 
1.0. The endpoints used included: i) Best objective response and ii) size change of target lesions 
as documented and centrally reviewed for each patient, iii) progression-free survival (PFS), 
defined as the interval from date of randomization to date of disease progression or death and 
iv) time to treatment failure (TTF), defined as the period from the date of randomization to that 
of end of study treatment for any reason (disease progression, patient’s choice, treatment 
toxicity or death). Both Karolinska Institute’s (Stockholm, Sweden) ethics committee (Dnr 02-
206) and Swedish Medical Product Agency have approved the clinical study and all the 
performed correlative analyses (included in paper V) for all participating centers. All patients 
have provided informed consent for their participation in the study. 
 
3.2 Gene expression profiling (GEP): RNA isolation, data generation, preprocessing, 
normalization and analysis 
A) GEP data derived from original study cohorts  
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i. The “Merck” early breast cancer cohort  
Total RNA was extracted from primary fresh frozen tumor tissue of all patients, using the 
Qiagen RNeasy Mini Kit, (Qiagen, Germany), and gene expression profiling was performed 
using NuGEN amplification protocol. Samples were then hybridized using the Rosetta/Merck 
Human RSTA Custom Affymetrix 2.0 microarray (NCBI GEO depository as GPL10379). 
Details about the experimental methods and microarray data (included in papers I-IV) are 
available at the Gene Expression Omnibus database, under the accession number GSE48091). 
In order to obtain a log-transformed expression value for each probe set, the raw GEP data 
were background corrected, normalized and summarized using the robust multichip averaging 
(RMA) (240) method implemented in the aroma.affymetrix R package (241). A nonspecific 
filter was used and in the case of multiple mappings to the same Entrez Gene ID, the probe sets 
with the highest interquartile range were chosen. The preprocessing and normalization of the 
GEP data were performed using R computing environment. 
 
ii. TEX metastatic trial  
As part of the translational aspect of the trial, metastatic biopsies were obtained mostly by fine-
needle aspiration biopsies (FNAB) (97.6%) or core biopsy (2.4%), in a total of 149 patients.  
In these patients, a biopsy from at least one metastatic site was taken before treatment start as 
follows: lymph nodes = 36.7%, liver = 22.5% skin = 18.3%, breast other sites = 6.7%. of the 
patients. RNA was subsequently extracted and its integrity was evaluated using the Agilent 
2100 Bioanalyzer (28S: 18S RNA ration). Samples were then profiled and hybridized using 
NuGEN protocol and Rosetta/Merck Human RSTA Custom Affymetrix 2.0 microarray (GEO: 
GPL10379), respectively (242). Further details regarding GEP data are available at the Gene 
Expression Omnibus database under accession number GSE56493. Before the differential 
expression analysis, a variance filter was employed (probes with a SD < the median SD for all 
probes were excluded) so as uninformative probe sets to be removed (242). 
 
iii. GEP data derived from The Cancer Genome Atlas (TCGA)  
The RNA sequencing data (RNA-seq v2 RSEM) for the evaluation of mRNA expression in the 
Provisional TCGA dataset (included in papers II and III), were downloaded from cBioportal 
(237, 238). These data (level 3) have been produced after i) alignment of the raw reads to the 
human h19 genome assembly using MapSplice (243), ii) quantitation at the gene (and isoform) 
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level using RSEM (244), and iii) application of upper-quartile normalization (245). In order to 
transfrom the normalized retrieved data to log2-expression, 1 was added to each value.  
 
iv. GEP data derived from pooled publicly available transcriptomic datasets 
A pooled gene expression analysis from thirty-nine publicly available datasets including 
transcriptomic profiles of more than 9500 primary breast cancers (papers I and IV for PD-L1 
and PD-1 gene expression, respectively) was performed. Gene expression data from the 38 
previously described public databases (246, 247) were retrieved and data from the Merck 
adjuvant cohort (GEO:GSE48091) (see above: patient populations and Gene expression 
profiling) were also added. In order for comparability of expression values across multiple 
datasets to be ensured, a robust linear scaling was applied to each gene such that expression 
quantiles 2.5% and 97.5% were set to −1 and +1, respectively. Due to incomplete information 
about ER and HER2 status among the datasets, ESR1 and ERBB2 status were classified based 
on the bimodal distribution of their expression values.  
 
3.3 Gene expression signatures  
i. PAM50 intrinsic subtypes (papers II, IV and V) 
The intrinsic molecular subtyping was assigned to each tumor using the research-based 50-
gene subtype predictor (PAM50) (248) and applied across the cohorts.  
Notably in paper II, a similar to the iterative approaches (249, 250) was used due to ER status 
discrepancies. In brief, GEP were matched to those derived from the original ER distribution 
in the original PAM50 report (248), in order an ER balanced subset to be formed. The whole 
dataset was median centred (as recommended in (251, 252)) and assigned to one of the intrinsic 
molecular subtypes. Samples with Spearman’s rank correlation coefficient < 0.1 were 
considered as not classified (250). More details can be found in the respective methods section 
of paper II 
Given that PAM50 signature was developed in a primary breast cancer cohort, as described in 
the original publication (248), the distribution of standard clinico-pathological markers (e.g 
ER, PR, HER2, nodal status, grade and size) was typical for the primary tumor setting. In 
contrast, the biological distribution is different in our TEX metastatic cohort material 
(presented in paper V) which includes tumors with more aggressive characteristics (e.g. ER-
negative and highly proliferative tumors). Therefore, the derived gene expression arrays were 
normalized with those derived from the primary breast cancer adjuvant Merck cohort (see 
above), profiled with the same platform (242).  Subsequent PAM50 subtyping was accordingly 
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performed (248) upon normalization and median centering across genes. Of note, both in this 
study and in the pooled gene expression datasets (used in papers I and IV), the normal breast-
like tumors were not included in the subgroup analyses, due to the lack of a clear established 
consensus on the existence of this subtype. 
Furthermore, for independent confirmation of the intrinsic subtyping the Absolute Intrinsic 
Molecular Subtyping (AIMS) approach was applied in the TEX trial (253).   
 
ii. 21-gene and 70-gene signatures (paper II) 
The research-based signature scores and risk classifications (used in paper II) were computed 
based on the originally described signatures for 21-gene (commercially known as OncotypeDx) 
(254) and 70-gene (commercially known as Mammaprint) (255), upon implementation in the 
genefu R/Bioconductor package (256). The procedure of signature application included median 
centering of the available GEP data and mapping of genes for both signatures through Entrez 
Gene IDs. The 21-gene signature included 5 reference genes that were not used in gene 
signature calculations while in the 70-gene signature there were 14 probes with unknown 
Entrez Gene IDs/ HUGO gene symbols and a couple of other probes which are missing from 
the platform (see paper II for gene availability in each cohort). 
 
iii. Phosphorylated STAT3-Associated Gene Signature (paper III) 
The phosphorylated STAT3-associated gene signature (pSTAT3-GS) was originally generated 
to predict trastuzumab resistance and shown to predict the proteomic pSTAT3 activation status 
(257). The provided pSTAT3-GS’s gene symbols were converted to Entrez Gene IDs using 
DAVID’s Gene ID Conversion Tool (258), and mapped both to the Merck’s and TCGA breast 
cancer cohorts microarray’s probe sets (paper III). The continuous signature scores, i.e., signed 
averages, were calculated using the genefu R package (256).  In total, out of the 123 
differentially expressed genes, 114 and 122 were mapped in Merck and TCGA datasets, 
respectively and subsequently used for the signature calculation.  
 
iv. Immune-related and other gene signatures (paper V) 
The predictive value of six gene expression signatures was explored in advanced breast cancer 
chemotherapy treated patients in the TEX trial (paper V), including: i) immune-related (48, 
121), ii) proliferation-related (259), iii) ER-related (260) and iv) the molecular aberrations-
related gene signatures for PIK3CA (261) and TP53 mutations (262). The weighted averages 
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(+1 or -1) of the expression values of the constituent signature genes were used for the 
calculation of the gene module scores (named as Immune module 1 and 2 (48), Proliferation, 
ESR1, PIK3CA and TP53 modules, respectively). A non-specific filter was first applied to the 
gene expression data and only original probe-sets or genes that could be mapped to Entrez 
Gene IDs where included in further analyses. In case of multiple probe-set mappings to the 
same Entrez Gene ID, those with the highest interquartile range were chosen. 
 
3.4 Bioinformatic tools for in silico analysis of immune cell subpopulations and TME 
i. CIBERSORT (paper II) 
For the further characterization and quantification/deconvolution of immune cell 
subpopulations using GEP-based data in the Merck cohort (paper II), the in silico CIBERSORT 
method (R script version 1.04) was employed (110). This computational approach and its gene 
signature matrix LM22 containing 547 genes, can distinguish 22 hematopoietic cell phenotypes 
from a bulk tumor tissue biopsy (263). Each patient in our cohort generated an absolute immune 
fraction score (median expression level of all genes in the signature matrix/median expression 
level of all genes in the mixture), with 100 permutations to be selected as a default. 
 
ii. Gene set enrichment analysis (paper V) 
In order to compare the differential expression of genes corresponding to important biological 
procedures between chemotherapy responders and non-responders in the TEX metastatic trial 
(paper V), gene set enrichment analysis (GSEA) of the Reactome gene sets collection in the 
Molecular Signatures Database (MSigDB, Broad Institute, version 5.2) was performed. The 
GSEA Software (Broad Institute, version 2.2.3) (115) was used and genes were pre-ranked 
through the R/Bioconductor package limma (version 3.30.4) (264). 
 
iii. Microenvironment Cell Populations counter (paper V) 
For the quantification and estimation of the absolute abundance of eight immune and two 
stromal cell populations derived from GEP data, the Microenvironment Cell Populations 
counter (MCP-counter) method was performed using the R package MCPcounter (version 
1.1.0) (112) in the same cohort (TEX trial; paper V) 
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3.5 Breast cancer tissue preparation and staining methods  
i. Tissue microarrays (TMAs) construction (papers I, II, IV) 
Tissue microarrays (TMAs) have been constructed from representative tumor-rich areas from 
all primary tumors in the Merck cohort, using an automated tissue microarrayer (VTA-100, 
Veridiam, San Diego, CA, USA). Each TMA consisted of duplicate per tumor and each core 
had a diameter of 1 mm. 
 
ii. Whole tissue sections from FFPE breast cancer tissue and cell lines (paper III) 
Whole tissue sections (4 um) were prepared from formalin-fixed paraffin-embedded (FFPE) 
tissue blocks for a subset of patients in Merck cohort according to the expression of PD-L1 in 
tumor cells (positive and negative). Furthermore, cell pellets from cultured breast cancer cell 
lines (MCF7, MDA-MB-231, BT549, see below) were collected, fixed in formalin and 
embedded in paraffin to prepare FFPE cell blocks and subsequent sections.  
 
iii. Immunohistochemistry (IHC) (papers I-IV) 
Tissue sections (4um) from the constructed TMAs were prepared and used for IHC. 
Immunostaining with the primary monoclonal antibodies targeting PD-L1 (clone SP263, 
Ventana, Roche; papers II and III), CD3 (clone 2GV6, Ventana, Roche; paper II) and PD-1 
(clone NAT105, Ventana, Roche; paper IV) were performed using the Ventana auto-stainer 
(Roche, Basel, Switzerland) according to the manufacturer’s protocol. Reactive lymphoid 
tissue of the tonsil was used as a control for both PD-L1 and CD3 IHC included. 
In FFPE sections of breast cancer cell line tissue blocks, IHC was manually performed using 
anti-phosphorylated STAT3/anti-pSTAT3Y705 (clone B-7. Santa Cruz Biotechnology), anti-
STAT3 (clone 79D7, Cell Signaling Technology) and anti-PD-L1 antibodies (clone EL1N3, 
Cell Signaling Technology), as briefly follows: i) slides’ deparaffinization and rehydration, ii) 
antigen epitope retrieval, iii) peroxide and protein blocking, iv) immunostaining with primary 
antibody (overnight incubation), v) primary antibody binding detection with a HRP-coupled 
polymer combined with DAB chromogen, vi) counterstaining with hematoxylin, vii) de-
hydration with gradient ethanol concentrations and viii) mounting. The anaplastic large 
lymphoma cell line Mac2A was used as a positive control for all these antibodies. 
Immunostaining with anti-pSTAT3Y705 (clone B-7. Santa Cruz Biotechnology) was also 
performed on whole tissue sections in a subset (n=83) of patients in the Merck cohort (paper 
III). Moreover, ER, PR (collected from pathology reports), HER2 (central evaluation using 
 
 40 
CISH) and Ki67 immunohistochemical staining and evaluation methods have been previously 
described in the Merck cohort (234). Sice ER, PR and HER2 positivity (either via IHC or FISH) 
was challenging to be defined in TCGA (265),  the reported statuses of the biomarker were 
used as described in the original publication (236). 
 
iv. Immunofluorescence (paper III) 
For the evaluation of macrophage markers’ expression in whole-tissue sections FFPE breast 
cancer patient tissue samples, double IF was performed as follows: i) antigen retrieval with 
sodium citrate buffer, ii) blocking using buffer containing PBS, 0.3% Triton X-100, 10% FBS 
and 1% BSA, iii) immunostaining with anti-CD163 (Leica) and anti-CD11c (Leica) antibodies 
and incubation with AlexaFluor 488 or 546 fluorochrome-conjugated secondary antibodies 
(Life Technologies) while cell nuclei were labeled with DAPI (Invitrogen Corp.). Binding 
specificity was ensured using isotype specific antibodies. For details regarding all antibodies 
see paper III (266). 
 
v. Hematoxylin and Eosin (H&E) staining (paper V) 
In order to evaluate the extent of lymphocytic infiltration in the advanced breast cancer setting, 
FNAB smears were stained by standard H&E (or Giemsa) staining protocols. 
 
vi. Fluorescence in Situ Hybridization (paper III) 
The CD274 gene locus status was analyzed on FFPE breast cancer cell pellets using FISH with 
the probe and protocols as recommended by the manufacturer (ZytoVision, GmbH). The 
validated CD274 probe expression (covering 9p24.1 gene locus) was quantified as copies under 
a fluorecescent microscope with a centromeric chromosome 9 probe as control. The ratio 
CD274/CEP9 ≥2 was considered as amplification (267-269).The Hodgkin lymphoma cell line 
HDML2 was used as positive control for CD274 amplification. 
 
3.6 Image acquisition, analysis and scoring methods  
i. Tissue microarrays (papers II and IV) 
PD-L1: PD-L1 was evaluated in tumor, immune cells and/or both cell types (total cell 
expression). PD-L1 positivity was defined by the presence of any single cell with membranous 
PD-L1 immunostaining (tumor or immune respectively). A TMA core was considered as PD-
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L1+ when at least one cell expressed the marker. In case of discordant expression between 
duplicate TMA cores, the positive one was selected 
CD3: CD3 IHC-stained TMA slides were digitally scanned (NanoZoomer-XR, Hamamatsu 
Photonics K.K, Japan) and manual scoring of the total number of CD3 positive (CD3+) cells 
was performed using ImageJ software v. 1.48 (NIH, Bethedsa, MD, USA). CD3+ membranous 
staining lymphocytes were counted in each TMA core and the average number was calculated 
over the duplicates (average number of CD3+ cells per tumor sample).  
PD-1: The total number of PD-1 positive cells, defined as the presence of any membranous 
immune cell staining, was manually counted under the microscope for each TMA core. The 
average number of PD-1+ positive cells was then calculated between the duplicate cores, thus 
representing the PD-1+ immune cells score per tumor sample.  
For all the aforementioned markers, the evaluation was performed by two independent 
investigators including a certified pathologist, while TMA cores with poor staining quality, 
limited or missing tumor, folded tissue were -upon discussion- excluded from the analysis.  
ii. Whole tissue sections (paper III) 
pSTAT3 IHC: Five different high power fields were selected per tissue section. At least 300 
tumor cells were manually counted using ImageJ software (NIH, Bethesda, MD, USA) and the 
percentage of pSTAT3 positive cells (nuclear expression) was subsequently calculated across 
the selected areas.  
Macrophage markers (CD163, CD11c) IF: Eight independent fields from each tumor section 
were analyzed using LSM T-PMT Zeiss confocal microscope. The abundance of positive cells 
over the total cell number was quantified per area using ImageJ software (NIH, Bethesda, MD, 
USA) and the average percentage of expression per marker was calculated across the selected 
areas. 
 
iii. Fine-needle aspiration biopsies (paper V) 
Lymphocytes on FNAB: For the quantitative assessment of immune infiltrate, an algorithm 
for lymphocyte counting in FNAB smears was developed. A minimum of 10 cancer-cell 
clusters containing at least 10 cells each were evaluated per smear. In each cluster, total number 
tumor cells and lymphocytes were separately enumerated and the average percentage of 




3.7 In vitro studies and laboratory techniques  
i. Cell Lines and culturing conditions (paper III) 
A number of cell lines were used in this study for the mechanistic in vitro studies including: a) 
the human breast cancer cell lines MCF7 and MDA-MB-231, BT549 and SKBR3, b) the mouse 
mammary carcinoma cell line 4T1, c) the anaplastic large cell lymphoma Mac2A cell line and 
d) the Hodgkin lymphoma cell line HDLM2. The cell lines were grown in complete RPMI-
1640 or DMEM media (Gibco/Life Technologies) supplemented with 10% FBS, 1% L-
glutamine and 1% penicillin/streptomycin and at 37 ◦C in 5% CO2 according to ATCC 
protocols. 
ii. Pharmacologic inhibition, transient transfections and gene silencing (paper III) 
Pharmacologic treatment on breast cancer cells was performed using the selective STAT3 SH2 
domain binder inhibitor C188-9 (Calbiochem) and recombinant human IL-6 (PeproTech) at 
indicated concentrations for 48h and 24h, respectively.  
Cells were seeded at a density of 0.2–0.6 × 106 cells/ml 24 h before prior transfection. The 
BT549 breast cancer cell line was transfected with siRNA oligonucleotide (300 nM) specific 
for the gene sequence of STAT3 and control siRNA (All Stars Negative, QIAGEN) using 
Lipofectamine 2000 (Thermofisher) reagent per protocol. The transfected SKBR3 breast 
cancer cells with vector control and STAT3C-plasmid (kindly provided by Drs Sarah Walker 
and David Frank, Department of Medical Oncology, Dana-Farber Cancer Institute, and 
Department of Medicine, Harvard Medical School, Boston, MA, USA). Whole cell lysates of 
the treated and transfected cells were then prepared for western blot analysis. 
The 4T1 mice tumor cells were transduced with lentiviral vectors encoding shRNA for murine 
Stat3 or corresponding control vector as previously described (270). Briefly, the shRNA 
plasmids have been amplified in bacteria and transfected to HEK293 cells in combination with 
plasmids producing lentiviruses. The supernatant of the cells including viruses containing the 
plasmids was collected and transduced to the 4T1 cells. The plasmid clone with the most 
efficient Stat3 gene silencing (as evaluated on whole-cell lysates via western blotting) was 
selected for the 4T1 mouse model  
 
iii. Western blot analysis (paper III) 
Immunoblotting was performed in cultured cells and the procedure can be briefly described as 
follows: tumor cells were collected, washed in cold PBS and lysed in lysis buffer (including 
protease and phosphatase inhibitors) for protein extraction. Protein concentration was then 
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detected using a spectrophotometric microplate reader. Samples were prepared with the desired 
concentration for gel electrophoresis and electrotransfer using PVDF membrane. The 
membrane was subsequently blocked (milk in TBST) and incubated with the primary antibody 
of interest. Last, the secondary antibody was incubated and band detection was performed using 
chemiluminescence method. More details about the antibodies used can be found in paper III. 
 
iv. RNA extraction, cDNA synthesis, and RT-qPCR (paper III) 
Total RNA was extracted from cultured breast cancer cell lines using the RNeasy® Plus Mini 
Kit (QIAGEN Inc.) and cDNA was synthesized with Superscript First Strand Synthesis System 
(Invitrogen), both according to the respective protocols. The expression of mRNA was 
quantified by RT-qPCR using the Power SYBR® Green PCR Master Mix (ThermoFisher 
Scientific) and the comparative CT (∆∆Ct) method. 18S rRNA and beta-actin were used as the 
endogenous control genes. The RT-qPCR program (performed in a Veriti 96-well thermal 
cycler) included: i) Amplitaq Gold DNA polymerase activation (95 ◦C for 10’), ii) 40 cycles 
of DNA denaturation (95 ◦C for 15’’) and iii) annealing (60 ◦C for 30’’).  
 
v. XTT proliferation assay (paper III) 
4T1-shCTR and 4T1-shStat3 murine tumor cells were seeded for 3 days at a density of 4 × 103 
cells/well (volume: 100ul each) in 96-well plates in complete RPMI-1640 medium. Six 
replicates were used for each cell line and time point (0, 24, 48 and 72 h). By using the Cell 
Proliferation Kit II, a mixture of XTT labeling with electron-coupling reagents was prepared 
per the manufacturer’s protocol. For each time point, measurement of cell viability was 
performed using a spectrophotometer (wavelength:490nm; reference: 650 nm). 
 
3.8 In vivo studies and animal models  
i. 4T1 breast cancer animal model and evaluation of the tumor growth (paper III) 
 2 × 105 4T1 (shCTR and shStat3) cells in a volume of 50 mL PBS were injected into the 
mammary fat pad of anesthetized 4-6 week-old female BALB/c mice (Charles River 
Laboratory). Mice were sacrificed 3 weeks after injection and tumors were dissected and 
weighed. Tumor size was measured using calipers, and tumor volumes were estimated based 
on the following equation: V = 4/3π × (d/2)2 × D/2, where d is the minor tumor axis and D is 
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the major tumor axis. Ethical permits regarding in vivo model were obtained from the Swedish 
Board of Agriculture (N95/15). 
 
ii. Flow Cytometric analysis of the immune microenvironment (paper III) 
Mice tumors were dissected into smaller pieces using scalpels, minced in dissociation buffer 
(TrypLe and Stem Cell Pro Accutase (Life Technologies); 1:1) and incubated at 37 ◦C for 30’ 
to the level of single-cell suspensions. Cell suspensions were subsequently passed through a 19 
G syringe needle, filtered and washed in PBS (including 10% FBS). For the flow cytometry 
analysis and in order to prevent nonspecific antibody binding, single-cell suspensions were 
incubated with anti-CD16/32 monoclonal antibody (BioLegend) on ice 15’ prior to the specific 
antibodies (for extracellular markers) incubation for 30’ on ice. T-regulatory (FoxP3+) cells 
were also stained following manufacturer’s instructions (BD Biosciences). Cells’ viability was 
verified using 7AAD or the Live/Dead fixable dead cell stain (Life Technologies). Samples 
were proceeded in the BD Biosciences LSR II flow cytometer and analyzed in FlowJo software 
(Tree Star, Ashland). Further details regarding antibodies and methods can be found in the 
respective paper III. 
 
iii. Pulmonary metastases colony assay (paper III) 
Lungs from the sacrificed were dissociated to the single cell level using an enzymatic buffer 
(RPMI, 5% FBS, 0.2 mg/mL collagenase IV, 0.2 mg/mL dispase (Life technologies) and 0.1 
mg/mL DNAse I (Sigma-Aldrich)) as described elsewhere (271-273). Cell suspensions were 
plated in the presence of 6-thioguanine (60uM) and the resistant ones were allowed to form 
colonies for 10 days and subsequently fixed with methanol, stained with crystal violet, and 
manually counted under a dissection microscope. 
 
3.9 Systematic reviews and meta-analyses  
i. Search strategy and study selection (papers I and IV) 
A trial-level meta-analysis of studies reporting on the prognostic value of PD-L1 (paper I) and 
PD-1 (paper IV) protein expression was conducted. A systematic electronic search was 
performed by a librarian at the Karolinska Institutet University Library in November 2018 and 
updated in May 2019, for the PD-L1 and PD-1 meta-analyses, respectively in the following 
databases: Medline (Ovid), Embase, Cochrane Library (Wiley) and Web of Science Core 
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Collection. English language was set as a restriction. The full search strategies can be found in 
the Supplementary Methods of both papers I and IV. Manual reference reviewing of selected 
review articles on the topic and of potentially eligible articles was performed in order to ensure 
that all relevant studies were included: Only studies which fulfilled the following criteria were 
included in our meta-analysis: studies investigating the prognostic role (measured as time-to-
event outcome) of PD-L1 expression (in tumor or immune cells) and PD-1 expression in 
patients with early-stage BC. We therefore excluded studies evaluating binary outcomes (as 
pathologic complete response) only, case reports, reviews, and meta-analyses. Two 
independent investigators performed study selection and consensus was reached in all eligible 
studies.  
ii. Data extraction and quality assessment (papers I and IV) 
Data were independently extracted by two investigators on a predefined form and a third 
investigator compared the databases for any discrepancies. The concordance rate between the 
2 investigators was 97.1% for the PD-L1 (paper I) and 97.8% for the PD-1 (paper IV) meta-
analyses. The data collected from each study included: first author’s last name, publication 
year, country where the study was conducted, retrospective or prospective type of study; 
method of PD-L1/PD-1 evaluation, tissue used for analysis, threshold for PD-L1 expression, 
antibody used; positivity rate of PD-L1 expression in tumor cells and/or immune cells and PD-
1 expression; study cohort characteristics of, follow-up time; outcome (time-to-event variables) 
for all patients data and within different BC subtypes -whenever feasible- and results from 
univariate and multivariable analyses 
The methodological quality of each eligible study was evaluated by two independent 
investigators using the tumor biomarker prognostic studies 20-item REMARK checklist (274), 
generating a score (maximum 40). A third investigator resolved any discrepancies. The 
concordance rate between the 2 investigators regarding quality assessment was 74.2% for the 
PD-L1 (paper I) and 70.0% for the PD-1 (paper IV) meta-analyses. 
 
3.10 Statistical Analyses 
i. Statistical methods used in the analyses of original study cohorts 
The chi-squared (χ2) test and Fisher’s exact tests were performed for the associations between 
categorical variables and assess any differences in clinicopathological characteristics between 
patient subgroups while Spearman’s rank correlation coefficient was used to evaluate the 
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associations between continuous variables. Student’s t-test and two-way ANOVA were used 
for comparisons between mean values on two groups 
Survival outcomes in the relevant groups were estimated using Kaplan-Meier curves and 
compared with the log-rank test. The survival R package was used for such analyses using the 
indicated endpoints. 
Univariate and multivariable Cox proportional hazards (PH) regression models were applied 
and unadjusted and adjusted HR and associated 95% CIs were estimated. The PH assumption 
was tested for all variables using the scaled Schoenfeld residuals. The set of covariates 
included the Cox models was selected on the basis of comparability and data availability 
among the training and validation cohorts as indicated and commonly included age, tumor 
size, lymph node status, subtypes and treatment. Exploratory interaction tests between the 
biomarker of interest and predefined clinical or PAM50-based subgroups and with survival 
outcome were evaluated in multivariable models.  
Specifically in paper II, the added prognostic value of PD-L1 gene to each gene-signature 
score was assessed using (a) the changes in the likelihood ratio test values (LR-Δ χ2), and (b) 
the concordance index (c-index: measure of goodness of fit for binary outcomes in a logistic 
regression model). Each gene-signature score was subsequently added either alone, or in 
combination with PD-L1 transcript expression to a Cox PH model with the corresponding 
clinical endpoint(s) for each cohort. 
In particular in paper V, the area under the receiver operating characteristic (ROC) curve was 
used for the performance of the additional exploratory predictive models. Cohen’s kappa 
coefficient was also used to measure agreement between molecular subtype assignments, as 
indicated whereas multiple testing in the GSEA was controlled by estimating the false 
discovery rate (FDR) (275). 
A p-value less than 0.05 (two-tailed) was used and considered as statistically significant. All 
statistical analyses were done in R/ Bioconductor computing environment (versions 3.3.2,  
3.5.1 and  3.6.2) and GraphPad Prism software version 7.0 (GraphPad Software Inc., San 
Diego, CA, USA) as indicated, unless otherwise stated. 
 
ii. Statistical methods for trial-level meta-analyses  
The first outcome of interest for the meta-analysis presented in paper I was the pooled PD-L1 
positivity rate in tumor cells/immune cells, or both. A random effects model was used for the 
calculation of an overall pooled PD-L1 expression positivity rate and also the respective 95% 
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CI, only if there were at least 3 studies (the same in each subgroup). The different subgroups 
where positivity rate was calculated were distinguished i) per BC subtype based on IHC criteria 
(ER+/HER2-, HER2+ and TNBC), ii) per antibody used, iii) per type of tissue (TMA versus 
whole-tissue sections) and iv) according to the threshold of positivity used. In order to test for 
differences of pooled rates among subgroups, chi-square statistics were used. A case was 
considered as PD-L1 positive when the respective protein expression by IHC was greater than 
the threshold used in each specific eligible study.  
The prognostic value of PD-L1 and PD-1 positivity was the second outcome of interest and 
time-to-event variables included DFS, RFS (end points merged in the meta-analysis given their 
almost identical definition) and OS. First, HR were calculated for all included studies for these 
specific variables as described in detail in papers I and IV. For each outcome of interest, HRs 
from both univariate and multivariate analyses for each eligible study were extracted and 
whenever possible meta-analyses were performed by pooling adjusted and unadjusted HRs 
separately. A threshold of 3 studies was set for subgroup analyses. 
The presence of statistical heterogeneity among the studies was assessed using the Q statistics 
and the magnitude of heterogeneity using the I2 statistic. A p-value <0.10 or an I2 value>50% 
denoted substantial heterogeneity. If substantial heterogeneity was observed, the fixed-effects 
model was used, otherwise we used the random-effects model. Moreover, potential publication 
bias was evaluated qualitatively using a funnel plot. Statistical analyses were performed using 
RevMan 5.3 (Review Manager, Version 5.3) and StatsDirect (StatsDirect Ltd. UK, 2013) and 
significance threshold for all reported p values (2-sided) was p <0.05. 
 
iii. Statistical methods for pooled gene expression analysis  
 Associations between PD-L1/PD-1 mRNA expression levels and DFS/DMFS/RFS/PFI and 
OS were investigated. Univariate and multivariate Cox regression models with scaled 
expression values (continuous variables) and stratification by cohort were fitted, and 
unadjusted and adjusted HR and CI were estimated. The multivariate Cox regression model, 
was adjusted for age, tumor size, lymph node involvement, histological grade, ESR1 and 
ERBB2 expression status (not in models by molecular subtype). Each METABRIC study site 
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4   RESULTS AND DISCUSSION  
 
Paper I: Prognostic implications of PD-L1 expression in breast cancer: systematic review 
and meta-analysis 
 
Given that the clinical utility of PD-L1 expression in BC remained questionable and in light of 
prior inconclusive reports, we aimed to comprehensively investigate PD-L1 protein positivity 
rates and the prognostic value of this biomarker both at the protein and mRNA levels in early 
BC through the performance of i) a systematic review and trial-level IHC-based meta-analysis 
and ii) a pooled gene expression analysis of 39 publicly available transcriptomic datasets (see 
methods above). Pooled PD-L1 positivity in tumor cells, immune cells or both in the entire 
population, per subtype, per antibody and was examined as well as its prognostic value for 
DFS/RFS and OS.  
The databases Medline, Embase, Cochrane Library and Web of Science Core Collection were 
searched up to November 2018 and data extraction was performed by two independent 
researchers. Of the initial 4,184 entries identified (2,746 entries upon de-duplication), 38 
retrospective studies fulfilled the predefined inclusion criteria for the trial-level meta-analysis. 
The overall pooled PD-L1 positivity rate in tumor cells was 24% (95% CI, 15–33%; 20 studies; 
n=10,404), 33% (95% CI, 14–56%; 5 studies; n=4,696) in immune cells and 25% (95% CI, 3-
59%; 4 studies; n=985) in both cell types. PD-L1 protein was mostly expressed in the triple-
negative BC subtype. Regarding antibody performance, the highest tumor positivity rate was 
reported with Dako 28-8 clone (39%; 95% CI, 26-52%, p<0.001).  
In the entire population, PD-L1 protein expression in tumor cells was an independent 
prognostic factor for shorter DFS (HR=1.62; 95% CI 1.14 – 2.33, p=0.008; I2 = 64%, 
pheterogeneity =0.003) and OS (HR=1.93; 95% CI 1.20 – 3.09, p=0.006; I2 = 80, pheterogeneity <0.001) 
as demonstrated in the multivariable analyses. In contrast, PD-L1 expression in immune cells 
was correlated with improved DFS (univariate HR=0.61; 95% CI 0.51 – 0.73, p<0.001; I2 = 
17%, pheterogeneity =0.29; 8 studies, n=969) and OS (univariate HR=0.53; 95% CI 0.39 – 0.73, 
p<0.001; I2 = 0%, pheterogeneity =0.57; 7 studies, n=857) in TNBC, with no significant 
heterogeneity in these subgroup analyses.  
In addition, higher PD-L1 gene expression was independently associated with improved 
survival in the entire population (multivariable HR=0.69, 95% CI 0.60 – 0.79, p<0.001, 
n=1,755 and HR=0.82, 95% CI 0.74 – 0.90, p<0.001, n=3,371  for DFS and OS, respectively) 
and in basal-like tumors (multivariable HR=0.53, 95% CI 0.38 – 0.74, p<0.001 and HR=0.64, 
95% CI 0.52 – 0.80, p<0.001 for DFS and OS, respectively). Significant interaction was 
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between PD-L1 expression and molecular subtype was observed only in the OS analysis 
(pinteraction0.005)  
PD-L1 expression as assessed by IHC is a clinically relevant biomarker in certain malignancies, 
since it may select appropriate candidates for immune checkpoint inhibition. The emerging role 
of PD-L1 expression and targeting especially in BC is reflected in the recent approval of the 
first anti-PD-L1 monoclonal antibody atezolizumab in combination with nab-paclitaxel in 
metastatic TNBC (203). Given that most of the benefit was demonstrated in the PD-L1 positive 
population and in light of several inconclusive reports using various IHC antibodies, scoring 
methods and cut-offs, there is an unmet need of discovering and validating predictive 
biomarkers.  
This study represents the largest meta-analysis on PD-L1 IHC expression and informs on PD-
L1 positivity rates and antibody selection as well as for the prognostic information of tumor 
versus immune cell expression. This is of interest for the design of clinical trials and sample 
size calculations since PD-L1 IHC expression selects a patient group with differential prognosis 
as candidates for immunotherapy.  
On the other hand, PD-L1 gene expression seems to represent a promising prognostic factor 
predicting better outcomes, especially in basal-like BC, as demonstrated in pooled gene 
expression analyses including a large number of patients. This finding is line with the higher 
levels of PD-L1 protein in the TNBC which can be attributed in the higher genetic and 
transcriptomic heterogeneity and immunogenicity of this molecular subtype (33). Of note, the 
observed discrepancy in the prognostic information between protein and mRNA levels, might 
be related to PD-L1 gene expression in the stroma. Therefore, there is a need for 
methodological standardization (both for antibody validation and for transcript detection) 
before implementation in the clinical routine and its use as a biomarker of treatment selection. 
Of note, PD-L1 expression was higher when evaluated in whole tissue sections as compared to 
tissue microarrays, supporting the use whole sections whenever available. 
Nonetheless, our study suffers from certain limitations that need to be addressed. The results 
among various studies are highly heterogeneous since different antibodies, cut-offs and scoring 
methods are used. The different patient populations and endpoint definition as derived from 
this trial-level (instead of individual patient level) meta-analysis also contribute to the 
substantial between-study heterogeneity, which was confirmed with the use of statistical tests. 
In addition, the limited number of studies did not allow for further subgroup analyses while the 
presence of publication bias might overestimate the true effect. Limitations and biases 
generated by pooled analyses of publicly available transcriptomic datasets have been 
previously described (276). 
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Paper II: PD-L1 mRNA expression as a prognostic marker in early BC patients and its 
additional prognostic value to 21-gene and 70-gene signature in ER+/HER2- disease  
 
Having summarized and demonstrated the prognostic value of PD-L1 expression (paper I) and 
given the few published studies including IHC and RNA data in the same cohort we aimed to 
a) compare the prognostic implications of PD-L1 expression between at the protein and mRNA 
levels and b) investigate if PD-L1 gene expression could provide added prognostic value in 
validated gene signatures, especially in ER+/HER2- subtype.  
The patient cohorts included i) our study cohort 1 (see Methods above, the “Merck” cohort) 
consisting of 562 primary BC patients with available gene expression profiling, tumor 
characteristics, treatment and follow-up data and ii) The Cancer Genome Atlas (TCGA) dataset 
consisting of 1081 patients with RNA-sequencing data (cohort 2). 
Immunohistochemical staining was performed in TMAs for anti-PD-L1 (Ventana; clone 
SP263) antibody and membranous positivity was defined separately in tumor and in immune 
cells (i.e macrophages, dendritic cells). PD-L1 was evaluable in 490/562 (87.2%) cases and 
expressed in tumor cells, immune cells and any cell type in 9.8%, 23.7% and 24.7% of the 
patients respectively (see Paper II:  Figure 2) and it was highly expressed among triple-
negative/basal-like subtypes. PD-L1 protein expression both in the tumor and immune cells 
was significantly correlated with better DMFI (univariate HR=0.58; 95% CI=0.39-0.87, p<0.01 
and multivariable HR=0.52; 95% CI=0.34-0.80; p<0.01) and OS (univariate HR=0.75; 95% 
CI=0.53-1.05, p=0.089 and multivariable HR=0.66; 95% CI=0.46-0.94; p<0.05). PD-L1 
protein was statistically significantly correlated with gene expression levels (Wilcoxon Mann-
Whitney, p< 0.001). Of note, tumors with higher PD-L1 transcript levels, were independently 
associated with better DMFI (HR=0.71; 95% CI=0.61-0.82; p<0.001) and OS (HR=0.77; 95% 
CI=0.67-0.87; p<0.001) both in the in the entire population as well as within basal-like and 
ER+/HER2- (HR=0.71; 95% CI=0.57-0.87; p>0.01) subtypes. Similar results were noted for 
PD-L1 gene expression with better PFI in the entire population in TCGA cohort (multivariable 
HR=0.76; 95% CI=0.64-0.91; p<0.01). 
We also demonstrated that PD-L1 gene expression added significant prognostic information 
beyond that of 21-gene signature (LR-Δχ2=15.289 and LR-Δχ2=8.812; p<0.01 for DMFI and 
PFI in cohorts 1 and 2, respectively) and the 70-gene signature (LR-Δχ2=18.198 and LR-
Δχ2=8.467; p<0.01 for DMFI and PFI in cohorts 1 and 2, respectively) alone using the 
likelihood ratio approach. Similar improved results were demonstrated for the addition of PD-
L1 gene to both 21-gene and 70-gene signature by using the c-indices method (see Paper 
II:Table 2) (277).  
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We also investigated the interplay among PD-L1 expression and immune cell subpopulations. 
Both PD-L1 protein and gene expression were correlated with increased IHC-determined 
CD3+ T-cell (r=0.41, p<0.001), expression in a subset of 412 patients.  CD3 expression was 
higher in triple-negative/basal-like subtypes and was also associated with improved survival. 
Furthermore, PD-L1 gene expression was positively associated with CD8+ (r=0.62, p<0.001) 
and CD4+ memory activated (r=0.66, p<0.001) but not with memory resting (r=-0.063, p=0.14) 
T-cells or T-regs (r=-0.12, p<0.01) as evaluated in silico (see Paper II: Supplementary Figure 
S4).  
 
Even though PD-L1 expression has been correlated with better prognostic capacity in early 
BC, the role of PD-L1 protein still remains inconclusive. To overcome the previous 
inconsistent results and analytical difficulties, we evaluated PD-L1 protein and gene expression 
at the same patient cohort. We showed in this study, that the use of this biomarker can improve 
prognosis of early BC patients. Therefore, while it seems that the prognostic information at the 
protein expression is more assay-dependent, PD-L1 gene expression might represent a 
promising factor. Moreover, a statistically significant correlation between protein and transcript 
levels was noted, as compared to previous reports (278, 279).  
Given that the currently used gene-expression signatures are mainly proliferation and estrogen 
receptor signaling-based and do not consider immune response, there might be room for further 
refinement as prognostic and predictive tools. The role of immune infiltration in combination 
with prognostic scores (immunohistochemistry-based IHC4 test including ER, PR, HER2 and 
Ki67; CTS, clinical treatment score including node status, size, grade, age and treatment; ROR; 
RS) for predicting risk of recurrence after endocrine therapy has been implied in a recent study. 
(280) We demonstrated in this study that PD-L1 can provide significant additional prognostic 
value to the prospectively validated 21- and 70-gene signatures in patients with ER+/HER2- 
early BC. This finding -upon proper validation- can lead to improved prognostication in these 
patients where gene signatures are indicated.  
In addition, in order to further delineate specific immune infiltration components in correlation 
with PD-L1, we immunohistochemically stained for the CD3 T-cell marker and we also 
analyzed the immune-related gene expression profiles using the bioinformatic tool 
CIBERSORT in the same patient cohort. We observed that PD-L1 expression associated with 
enhanced T-cell infiltration and therefore may represent a surrogate of effective anti-tumor 
immunity. 
Whether the observed effect of PD-L1 can be solely attributed to the prognostic information or 
it is associated is chemotherapy prediction (see also paper V) remains questionable. The 
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potential predictive role of PD-L1 as a driver of chemosensitivity in the adjuvant setting of 
ER+/HER2- BC, could not be demonstrated here due to limited number of time-to-event and 
lack of randomization to chemo/no chemo-treated arms and therefore merits further 
investigation. Nevertheless, the clinical cohorts used in this study included both lymph node-
positive and negative patients, thus hindering the direct clinical interpretation of our results on 
the added prognostic value to gene-signatures in this setting. Therefore, it is still unclear if it 
can identify patients with low risk of relapse who can safely forego adjuvant chemotherapy. 
Another limitation of this study is that the gene-signatures used are not the commercial version 
and the lower gene representation may affect their prognostic performance. Moreover, due to 
the retrospective nature of the included cohorts, we only managed to demonstrate the clinical 
validity of PD-L1 expression as a biomarker in early BC. In order to prove any possible clinical 
utility, prospective clinical trials needed to be designed. In addition, the evaluation of PD-L1 
was performed on TMAs instead of whole tissue sections, the spatial heterogeneity of 























Paper III: STAT3-mediated the regulation of Programmed-Ligand 1 expression and 
immune profile modification in BC 
 
Having previously reviewed the complex, multi-level regulation of PD-L1 (140), we aimed to 
explored potential mechanisms of PD-L1 regulation in BC, focusing on the 
oncogene/transcription factor STAT3. We showed that in breast cancer patients, a pSTAT3-
GS was positively significantly associated with PD-L1 protein positivity (Wilcoxon, p = 
0.0027, n=539) and PD-L1 gene expression in two independent patient cohorts (Spearman’s 
rho = 0.34, p<0.01 and Spearman’s rho = 0.38, p < 0.01 in the Merck cohort and TCGA, 
respectively). We also demonstrated in these two cohorts that pSTAT3 and PD-L1 transcripts 
were highly expressed in triple-negative as compared to non-TNBC subtypes.  
In order to further confirm these findings, we evaluated protein expression in three different 
breast cancer cell lines using immunoblotting and immunohistochemical methods. We 
demonstrated that both pSTAT3 and PD-L1 presented with higher expression in TNBC cell 
lines (MDA-MB-231 and BT549) compared the non-TNBC cells (MCF7). Given these 
correlations and the lack of genetic amplification of PD-L1 in the cancer cell lines used (also 
shown in our study), we explored potential STAT3-mediated regulatory mechanisms of PD-
L1. By using the selective pharmacologic STAT3 inhibitor C188-9 (XIII) and siRNA STAT3 
gene knockdown we observed a downregulation of PD-L1 expression. In addition, 
overexpression of STAT3 gene expression using a constitutively actively plasmid as well as 
treatment with IL-6, led to increased pSTAT3 and PD-L1 expression. Taken together, we 
provided evidence that STAT3 transcriptionally regulated PD-L1 expression in breast in vitro.  
Furthermore, when Stat3 gene was silenced in the murine triple-negative 4T1 tumor cell line, 
PD-L1 gene was also down-regulated. In order to evaluate the effects of Stat3 gene silencing 
in vivo, we injected the mouse tumor cells (shCtrl and shStat3) into mammary fat pad of  balb/c 
mice and generated a murine 4T1 breast carcinoma model. Stat3 gene silencing led to reduced 
tumor growth Day 25: 36.7%) and weight (Day 25: 31.3%) as well as to fewer pulmonary 
metastases compared to control mice. When investigating the immune infiltrate composition 
using flow cytometry, we demonstrated that Stat3 gene silencing was accompanied by anti-
tumoral macrophage (increased F4/80+ and MHCII) and NK cell (CD69) accumulation but 
surprisingly by reduction of CD8+ T-cells and increase of T-regulatory cells, indicating the 
association of Stat3 with an altered immune profile. 
Based on the observed macrophage phenotype shift in vivo, we also evaluated the expression 
pattern of macrophage phenotypes in breast cancer patients using immunofluorescence. We 
observed that pro-tumoral “M2-like” macrophage phenotype (CD163+) was correlated with 
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PD-L1 tumor cell protein expression and gene expression in breast tumors. Similar associations 
were noted among PD-L1 tumor cell expression and higher tumor grade and proliferation, thus 
indicating a biologically high-risk phenotype.  
 
STAT3 represents an oncogene and an important transcription factor involved in several 
cellular functions, such as cell proliferation, invasiveness and metastasis (144) and recently in 
anti-tumor immune response, including immune checkpoints molecules and immune cell 
subpopulations in various tumor types (145). Even though the STAT3-mediated transcriptional 
regulation of PD-L1 has been previously reported (282, 283) a comprehensive approach on the 
role of STAT3 as a regulator of anti-tumor immune including in vitro, in vivo and patient 
material has not been reported in BC. 
Upon Stat3 silencing, NK cell and macrophage accumulation as well as the skewness towards 
a more anti-tumoral “M1-like” phenotype significantly contributed to the reduced tumor 
growth and burden in vivo. The surprisingly observed CD8+ T-cell decrease and T-reg 
accumulation in the shSTAT3 tumors might be explained by the undetermined role of PD-L1 
expression in immune cells (284) rather than only in tumor cells explored here. The decreased 
index of pulmonary metastases further underscores the impact of pro-tumoral “M2-like” in the 
metastatic potential (285). 
We also showed that pro-tumoral macrophages were correlated to PD-L1 tumor cells 
expression in a subset of patients, contributing to an immunosuppressive phenotype. These 
finding are in line with the poor prognostic capacity of both PD-L1 tumor cell expression (paper 
I) and M2-like macrophages (100) in early breast cancer. Although few studies in other cancer 
types have reported such association (286) it is likely that the two distinct macrophage 
phenotypes can secrete cytokines and others factors which modifies PD-L1/PD-1 expression 
and anti-tumor immunity (287, 288). 
The interplay of STAT3 with PD-L1 and immune profile in breast cancer might have potential 
clinical implications and pave the way for future therapeutic strategies with immune checkpoint 
blockade in combination with STAT3 inhibitors, since they are current ongoing trials testing 
their efficacy, especially in TNBC patients (289). Moreover, immune checkpoint inhibitors 
could be combined with macrophage accumulating and/or re-programming agents (e.g., CSF-
1 inhibitors) in selected breast cancer patients, which are currently under clinical investigation 
(288, 290). Last but not least, identification of patient subgroups might lead to prognostic and 






Paper IV: Prognostic value of PD-1 protein and mRNA expression in early breast cancer  
 
Despite the high interest on PD-1 blockade and the development of monoclonal antibodies, 
only few studies exist on the prognostic capacity of PD-1 expression in BC, which still remains 
unclear. Our study comprised three different parts:  i) Immunohistochemical evaluation PD-1 
protein on tissue microarrays and gene expression in our retrospective original study cohort 
comprising of 564 patients treated for early BC between 1997-2005 in Stockholm, Sweden (see 
also methods: patient populations); ii) Systematic review and an IHC study-based meta-
analysis with literature search up to May 2019; and iii) Pooled analysis of transcriptomic data 
from 39 publicly available datasets (see also paper I).  
In the study cohort, 220/564 (46.7%) of the patients demonstrated PD-1 positive protein 
expression in immune cells which was significantly correlated to characteristics such as 
estrogen receptor-negativity and high proliferation rate (p<0.001). Nevertheless, BC patients 
with high PD-1 protein expression were associated with improved DRFI (multivariable HR = 
0.66, 95% CI 0.48 – 0.91, p=0.010) and OS (multivariable HR=0.73, 95% CI 0.55 – 0.97, 
p=0.027). In contrast, PD-1 gene expression was not found to significantly predict survival 
outcomes DRFI (HR=0.88, 95% CI 0.66 – 1.18, p=0.399) and OS (HR=0.88, 95% CI 0.68 – 
1.13, p=0.312) as revealed in multivariable analyses. Moreover, no significant interaction was 
noted between PD-1 expression and IHC-based subtype in the subgroup survival analyses. A 
weak statistically significant correlation was also demonstrated between PD-1 mRNA and 
protein expression levels cohort (Spearman’s rho=0.123, p=0.007). 
In the first -to date- reported meta-analysis on the prognostic information of PD-1 expression, 
4736 initial entries (3298 entries upon de-duplication) were identified. Study selection, data 
extraction (concordance rate = 97.8%) and quality assessment (concordance rate = 70%) were 
performed by two independent investigators and a total of 15 retrospective studies -including 
our study cohort- that fulfilled the predefined eligibility criteria were included in the analysis. 
PD-1 protein expression did not significantly predict survival outcomes in the entire 
population. Interestingly, it was correlated with improved DFS in the TNBC subtype (3 studies, 
n=417; pooled multivariable HR = 0.57; 95% CI 0.29 – 0.90; p-value = 0.02). 
Furthermore, a pooled gene expression analysis from 39 available public databases (n= 9493) 
(see also paper I), including GEP data from our original cohort, was performed. High PD-1 
gene expression was associated with significantly improved OS (pooled multivariable 
HR=0.89; 95% CI 0.80 – 0.99; p=0.025) but not DFS in the entire population. Within molecular 
subtypes, higher PD-1 transcript levels predicted better OS in the basal-like (pooled 
multivariable HR=0.77, 95% CI 0.63 – 0.95, p=0.014) and HER2-enriched (pooled 
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multivariable HR=0.78, 95% CI 0.61 – 0.98, p=0.032) subtypes, although no significant 
interaction was detected (pinteraction = 0.185). 
 
We demonstrated that PD-1 protein and gene expression correlated to improved prognosis in 
early BC patients, especially in the triple-negative/basal-like subtypes, using a multi-level 
approach (the only to date meta-analysis on PD-1 IHC expression and the largest pooled gene 
expression analysis).  Similar prognostic capacity in these highly immunogenic subtypes was 
also noted for PD-L1 expression (see paper I) -especially in the immune cells- further 
highlighting the crucial role of TME. Given that PD-1 is generally considered as a co-inhibitory 
immune molecule, a number of reports indicate that PD-1 could represent a marker of T-cell 
activation and receptor signaling rather than a T-cell exhaustion indicator (80, 130), which can 
be defined by other immune checkpoints (i.e TIM-3, LAG-3, CD39) (291), Of note, PD-
1+CD8+ cells have been correlated to better survival (187), underscoring the need of a 
comprehensive understanding of the specific immune composition and expression patterns. 
PD-1 has been also linked to T-cell activation-associated gene expression in patients with BC 
(292), further indicating a marker of an effective anti-tumor immune response.  
Of note, in terms of prognostic information in our study cohort, a discrepancy was noted 
between PD-1 protein and gene expression levels. PD-1 IHC analytical difficulties seem to be 
fewer, as compared to PD-L1 (178), since an antibody clone is commonly used and its 
expression is observed on immune cells (128). Nonetheless, the weak significant correlation 
observed between PD-1 mRNA and protein expression in the study cohort question the 
reliability of IHC evaluation of this marker, although data on PD-1 mRNA expression as a 
prognostic biomarker are scarce (187). Given the complex post-transcriptional/translational 
regulation of PD-1 expression (293), there is a need for further validation of the genomic 
detection methods and prospective evaluation of its clinical utility.        
The limitations of this study include: i) the few retrospective studies which did not allow for 
further subgroup analyses, ii) the heterogeneous patient populations and IHC scoring methods 
which introduced significant heterogeneity, iii) the trial-level meta-analysis instead of an 
individual patient data analysis, iv) the evaluation of PD-1 protein on TMA rather than in whole 
tissue section which possibly underestimated the spatial expression heterogeneity in our study 
cohort which was also v) of a small size and vi) had an overrepresentation of biologically 
aggressive tumors (higher histological grade, proliferation rate, larger size, more lymph node 
metastases and younger patients); vi) biases and limitations introduced by the analysis on 




Paper V: Immune gene expression and chemotherapy response in advanced BC 
 
Considering the promising capacity of gene expression signatures as predictors of response to 
neoadjuvant chemotherapy in breast cancer, we investigated the predictive role of intrinsic 
molecular subtypes and modules including immune response, ER signaling, proliferation, 
PIK3CA and P53 mutations, using the gene expression profiles obtained at baseline from fine 
FNAB of metastatic BC tissue in 109 patients treated with first-line chemotherapy in the TEX 
phase III clinical trial (epirubicin and paclitaxel +/- capecitabine).  
Two non-overlapping immune response signatures (48, 121) were used and one of them was 
statistically significantly correlated with higher probability of achieving objective response to 
chemotherapy (per standard deviation odds ratio (OR) = 1.62; 95% CI, 1.03–2.64; P=0.04) in 
the entire population. However, both investigated immune modules showed a consistently 
significant high predictive value in ER positive (per s.d. odds ratio (OR) 2.05, 95% CI 1.11 – 
4.13, p=0.02 and per s.d OR 2.23, 95% CI 1.21 – 4.48, p=0.01  for the two modules) and 
luminal cancers (per s.d. odds ratio (OR) 6.91, 95% CI 2.11 – 35.05, p=0.006 and per s.d OR 
3.54, 95% CI 1.43 –10.86, p=0.01), but not in ER-negative or non-luminal tumors. An 
independent GSEA confirmed that that immune-related gene sets (including PD-1 signaling 
and interferon-γ) were enriched in ER-positive or molecularly luminal responders.  
In order to evaluate the extent of lymphocytic infiltration in this setting we performed H&E or 
Giemsa staining on FNAB material from various metastatic sites (evaluable smears on 50/109 
patients) in order to generate a scoring algorithm for lymphocytes enumeration. We reported 
scarce TIL counts (median 1.3% of the total cells; IQR: 0.6-2.3%) and low correlation with 
immune modules (Spearman’s rho= 0.26 and 0.18), with no predictive effect to chemotherapy. 
Moreover, for the in silico calculation of absolute abundance of immune and stromal cell types, 
we used the MCP-counter method. Lymphocytes and monocytes were associated with 
increased chemosensitivity in the ER-positive and luminal subgroups without outperforming 
the one observed with the two immune-related gene modules. 
 
The favorable prognostic capacity of tumor-infiltrating lymphocytes has been demonstrated in 
triple-negative and HER2-positive BC patients both in adjuvant and neoadjuvant settings (39, 
43). TILs also carry predictive information for benefit to neoadjuvant chemotherapy, leading 
to improved pCR rates (43), although not well studied in the metastatic setting. Moreover, even 
though gene expression signatures have been used for treatment prediction in the neoadjuvant 
setting (122), their predictive value in advanced breast cancer is largely unknown. Subgroup 
analyses of two large randomized immune checkpoint blockade clinical trials, IMPassion130 
 
  59 
(163, 202) and KEYNOTE-119  (164), evaluating PD-L1 protein expression,  revealed that the 
effect on PFS or OS respectively in the chemotherapy-only arm was the same irrespective PD-
L1 status in patients with metastatic TNBC. 
 
Taken together, we have shown for the first time that in patients with ER+ and luminal 
advanced BC, immune-related gene signatures could statistically significantly predict response 
to chemotherapy, paving the way for the development of novel immune-based predictive 
factors of chemosensitivity in luminal tumors which are considered as less immunogenic and 
highly heterogeneous (294). The results of this study indicate that an active immune 
microenvironment (as reflected by the use of largely non-overlapping immune signatures used 
in this study) may carry the predictive information and not specific genes, since a single marker 
is possibly unable to grasp the complexity of tumor-host interactions. Indeed, the release of 
neoantigens which can trigger anti-tumor immune response may be a crucial step towards the 
induction of immunogenic cancer cell death (198). 
Furthermore, we tried to explore the predictive role of PD-L1/PD-1 a driver of 
chemosensitivity in the adjuvant setting of ER+/HER2- BC using both our study cohort as well 
as public available datasets (see paper II). This hypothesis could not be proven due to limited 
number of time-to-event and therefore merits further investigation in trials included 
chemotherapy-treated vs non-chemotherapy BC patients. To determine the predictive role of 
tumor immune infiltration for the effect of adjuvant chemotherapy especially in luminal BC, a 
large prospective trial is needed including both chemo-treated and untreated patients.  
Nevertheless, there are limitations of our study which need to be acknowledged. There is no 
other similar metastatic cohort -to date- with available GEP data in order to validate our 
findings and investigate if the results can apply to other chemotherapeutic drugs or other 
treatment lines or treatment types. This concept needs to be further validated in a prospective 
randomized trial, considering the limitations emerged by the prospective-retrospective 
approach of this analysis and the small number of patients. 
Although our hypothesis is that patients with high TILs are expected to better respond to 
chemotherapy, this could not be tested here since the numbers of lymphocytes detected were 
too low. Moreover, given the lack of TILs evaluation guidelines in the metastatic BC setting 
and the paucity of studies with available material from the various metastatic sites hinder the 
further validation our scoring method while number of TILs is also lower in metastases 
compared to the primary tumor (60). Inter-observer and intra-observer variability despite 
guidelines for the interpretation of slides, dependency on biopsy methodology and risk of 
sampling biases are also among the relative disadvantages of TILs as a biomarker in advanced 
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breast cancer. At the same time, fine needle aspiration biopsy material does not take into 
account the TIME interactions as compared to metastatic core biopsies and this could probably 
explain the lack of prediction in the ER-negative subgroup where the presence of stroma drives 
immunogenicity. However, despite the sampling difficulties, tumor heterogeneity in metastatic 
biopsies (295, 296) dictates a shift from the cancer cell-centric concept to that of the TME 
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4 CONCLUSIONS AND FUTURE PERSPECTIVES 
 
Given the complex regulation, the emerging role of PD-L1/PD-1 signaling axis as a biomarker 
and immunotherapeutic target in BC and the complex interactions among tumor and immune 
cells, the present doctoral thesis aimed to shed light in some of these aspects. The conclusions 
and clinical implications that can be drawn from these studies are: 
• PD-L1 protein expression in tumor cells is poor prognostic factor, whereas PD-L1 
expression in immune cells is a favorable one in the TNBC subtype 
• PD-1 protein expression is correlated with improved outcomes in basal-like/TNBC 
subtypes 
• PD-1 and PD-L1 gene expressions are promising prognostic biomarkers, predicting 
improved survival outcomes especially in in basal-like/triple-negative subtypes 
• PD-L1 mRNA expression adds significant prognostic value to prospectively validated 
21- gene and 70-gene signatures in ER+/HER2- disease 
• Immune-related gene signatures are predictive for chemosensitivity in luminal 
advanced breast cancer 
• T-cell infiltration and pro-tumoral macrophages are correlated with PD-L1 protein 
expression 
• STAT3 represents a regulator of PD-L1 expression in BC in vitro and modulates 
antitumor immune response mainly through macrophage phenotype shift, 
acummulation of NK cells and T-lymphocytes in vivo 
External validation of our findings and standardization of PD-L1/PD-1 detection methods are 
of utmost importance. Protein evaluation in the immune cells and gene expression as 
biomarkers could improve prognostication and further refine currently available gene 
expression signatures and patient management algorithms. The main concept of 
immunotherapy with the release of immunological “brakes” which dampen the immune 
response through exhaustion cytotoxic T-lymphocytes has led to the introduction of immune 
checkpoint inhibitors. Even though PD-1/PD-L1 axis blockade has met with success during the 
past years with durable responses and increased efficacy, there are still two major barriers that 
need to be considered before for the integration of such new therapies: toxicity and financial 
cost. Close monitoring of the patients will contribute to the recognition of the immune-related 
adverse events and enhance the potential for combinational immune checkpoint inhibition. At 
the same time, immunotherapy revolution is accompanied by increased cost and thus cost-
effectiveness issues should be also considered for each treatment option. Moreover, despite the 
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exciting developments in this rapidly evolving field, only a minority of the potential immune-
related markers and therapeutic targets have been comprehensively investigated. Other 
determinants of anti-tumor immune response need to further clarified using the emerging 
multiplexed imaging and multi-omics technologies, which might expand the therapeutic 
armamentarium for BC patients. More research is also warranted towards further elucidation 
of the underlying regulatory mechanisms driving PD-L1/PD-1 expression and antitumor 
immunity as well as their clinical implications especially in the highly heterogenous BC in 
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